<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="30ca5702-272c-7528-e063-6294a90abbc1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 <br/>
      <br/>
INVOKANA 
 <sup>Â®</sup>(canagliflozin) tablets, for oral use
 <br/>
Initial U.S. Approval: 2013
</title>
   <effectiveTime value="20250320"/>
   <setId root="b9057d3b-b104-4f09-8a61-c61ef9d4a3f3"/>
   <versionNumber value="31"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="063137772"/>
            <name>Janssen Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="053217022"/>
                        <name>AndersonBrecon Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="063137772"/>
                        <name>Janssen Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="400344443"/>
                        <name>Ajinomoto OmniChem</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="400345889"/>
                        <name>Janssen Pharmaceutica NV</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="542797928"/>
                        <name>Janssen Cilag SpA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="805887986"/>
                        <name>Janssen-Ortho LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30ca7a73-b695-bb1c-e063-6294a90a3e13"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50458-140" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INVOKANA</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>canagliflozin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0SAC974Z85" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CANAGLIFLOZIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6S49DGR869" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CANAGLIFLOZIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-140-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-140-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-140-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50458-140-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20130329"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-140-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA204042" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20130329"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CFZ;100</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50458-141" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INVOKANA</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>canagliflozin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0SAC974Z85" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CANAGLIFLOZIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6S49DGR869" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CANAGLIFLOZIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-141-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-141-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-141-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50458-141-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20130329"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50458-141-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20130329"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA204042" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20130329"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="17" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CFZ;300</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="2a427270-3138-bf22-e063-6294a90aaa69"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="60%" align="left" valign="top"/>
                           <col width="40%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (
    
       <linkHtml href="#S1">1</linkHtml>)
   
      </td>
                                 <td>12/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (
    
       <linkHtml href="#S2.2">2.2</linkHtml>,
    
       <linkHtml href="#S2.3">2.3</linkHtml>)
   
      </td>
                                 <td>12/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (
    
       <linkHtml href="#S2.5">2.5</linkHtml>)
   
      </td>
                                 <td>08/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (
    
       <linkHtml href="#S5.1">5.1</linkHtml>)
   
      </td>
                                 <td>08/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (
    
       <linkHtml href="#S5.2">5.2</linkHtml>)
   
      </td>
                                 <td>08/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2a427270-3139-bf22-e063-6294a90aaa69"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>INVOKANA (canagliflozin) is indicated:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange">as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.</content>
                     </item>
                     <item>to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).</item>
                     <item>to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.</item>
                  </list>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (
  
     <linkHtml href="#S1">1</linkHtml>).
 
    </item>
                           <item>To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (
  
     <linkHtml href="#S1">1</linkHtml>).
 
    </item>
                           <item>To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (
  
     <linkHtml href="#S1">1</linkHtml>).
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus (
  
     <linkHtml href="#S1">1</linkHtml>).
 
    </item>
                           <item>Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m
  
     <sup>2</sup>(
  
     <linkHtml href="#S1">1</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="2a427270-313a-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>INVOKANA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">INVOKANA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m
 
   <sup>2</sup>. INVOKANA is likely to be ineffective in this setting based upon its mechanism of action.

  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="2a427270-313b-bf22-e063-6294a90aaa69"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating (
  
     <linkHtml href="#S2.1">2.1</linkHtml>).
 
    </item>
                           <item>The recommended starting dosage in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus is 100 mg orally once daily, taken before the first meal of the day to improve glycemic control. The dosage can be increased to 300 mg once daily in patients tolerating 100 mg once daily who have an eGFR of 60 mL/min/1.73 m
  
     <sup>2</sup>or greater and require additional glycemic control (
  
     <linkHtml href="#S2.2">2.2</linkHtml>).
 
    </item>
                           <item>For all other indications in adults, the recommended dosage of INVOKANA is 100 mg orally once daily (
  
     <linkHtml href="#S2.2">2.2</linkHtml>).
 
    </item>
                           <item>Dosage adjustments for patients with renal impairment may be required (
  
     <linkHtml href="#S2.3">2.3</linkHtml>).
 
    </item>
                           <item>See full prescribing information for INVOKANA dosage modifications due to drug interactions (
  
     <linkHtml href="#S2.4">2.4</linkHtml>).
 
    </item>
                           <item>Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting (
  
     <linkHtml href="#S2.5">2.5</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="2a427270-313c-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Prior to Initiation of INVOKANA</title>
                     <text>
                        <paragraph>Assess renal function before initiating INVOKANA and as clinically indicated
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>and
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>In patients with volume depletion, correct this condition before initiating INVOKANA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>and
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="2a427270-313d-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage and Administration</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-313e-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years and Older</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="xmChange">The recommended starting dosage of INVOKANA is 100 mg orally once daily to improve glycemic control, taken before the first meal of the day.</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">For additional glycemic control, the dosage of INVOKANA may be increased to the maximum recommended dosage of 300 mg once daily.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-313f-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Recommended Dosage for Other Indications in Adults</paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The recommended dosage of INVOKANA is 100 mg orally once daily for the following indications in adults:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="xmChange">to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).</content>
                                 </item>
                                 <item>
                                    <content styleCode="xmChange">to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2a427270-3140-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older with Renal Impairment</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Table 1 provides dosage recommendations for adults and pediatric patients aged 10 years and older with renal impairment, based on estimated glomerular filtration rate (eGFR).</content>
                        </paragraph>
                        <table width="80%" ID="tab1">
                           <caption>Table 1: Recommended Dosage in Adults and Pediatric Patients Aged 10 Years and Older with Renal Impairment</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Lrule Rrule">Estimated Glomerular Filtration Rate 
     <br/>  [eGFR (mL/min/1.73 m
    
     <sup>2</sup>)]
   
    </th>
                                 <th align="center" styleCode="Rrule">Recommended Dosage</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">eGFR 30 to less than 60</td>
                                 <td styleCode="Rrule">The maximum recommended dosage is 100 mg orally once daily.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">eGFR less than 30</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered">
                                       <item>Initiation is not recommended</item>
                                       <item>Adult patients taking INVOKANA with albuminuria greater than 300 mg/day may continue INVOKANA 100 mg once daily to reduce the risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for heart failure
      
       <content styleCode="italics">[see
       
        <linkHtml href="#S1">Indications and Usage (1)</linkHtml>and
       
        <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].
      
       </content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="2a427270-3141-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Concomitant Use with UDP-Glucuronosyl transferase (UGT) Enzyme Inducers</title>
                     <text>
                        <paragraph>When co-administering INVOKANA with an inducer of UGT (e.g., rifampin, phenytoin, phenobarbital, ritonavir), increase the dosage of INVOKANA based on renal function
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]:
 
  </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>In patients with eGFR 60 mL/min/1.73 m
  
   <sup>2</sup>or greater, increase the dosage to 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily. The maximum recommended dosage of INVOKANA is 300 mg once daily.
 
  </item>
                           <item>In patients with eGFR less than 60 mL/min/1.73 m
  
   <sup>2</sup>, increase to a maximum recommended dosage of 200 mg orally once daily in patients currently tolerating INVOKANA 100 mg once daily.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="2a427270-3142-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Temporary Interruption for Surgery</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume INVOKANA when the patient is clinically stable and has resumed oral intake
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>and
  
    <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>].
 
   </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="2a427270-3143-bf22-e063-6294a90aaa69"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>INVOKANA 100 mg tablets are yellow, capsule-shaped, tablets with "CFZ" on one side and "100" on the other side.</item>
                     <item>INVOKANA 300 mg tablets are white, capsule-shaped, tablets with "CFZ" on one side and "300" on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 100 mg, 300 mg (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="2a427270-3144-bf22-e063-6294a90aaa69"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>INVOKANA is contraindicated in patients with a serious hypersensitivity reaction to INVOKANA, such as anaphylaxis or angioedema
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>and
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>,
  
   <linkHtml href="#S6.2">6.2)</linkHtml>]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Serious hypersensitivity reaction to INVOKANA (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="2a427270-3145-bf22-e063-6294a90aaa69"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis</content>: Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue INVOKANA if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting (
  
     <linkHtml href="#S5.1">5.1</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Lower Limb Amputation</content>: Monitor patients for infection or ulcers of lower limb and discontinue if these occur (
  
     <linkHtml href="#S5.2">5.2</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Volume Depletion</content>: May result in acute kidney injury. Before initiating INVOKANA, assess and correct volume status in patients with renal impairment, elderly patients, or patients on loop diuretics. Monitor for signs and symptoms during therapy (
  
     <linkHtml href="#S5.3">5.3</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Urosepsis and Pyelonephritis</content>: Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated (
  
     <linkHtml href="#S5.4">5.4</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</content>: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA (
  
     <linkHtml href="#S5.5">5.5</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Necrotizing Fasciitis of the Perineum (Fournier's Gangrene)</content>: Serious, life-threatening cases have occurred in both females and males. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment (
  
     <linkHtml href="#S5.6">5.6</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Genital Mycotic Infections</content>: Monitor and treat if indicated (
  
     <linkHtml href="#S5.7">5.7</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Discontinue INVOKANA and monitor until signs and symptoms resolve (
  
     <linkHtml href="#S5.8">5.8</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Bone Fracture</content>: Consider factors that contribute to fracture risk before initiating INVOKANA (
  
     <linkHtml href="#S5.9">5.9</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="2a427270-3146-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis</title>
                     <text>
                        <paragraph>In patients with type 1 diabetes mellitus, INVOKANA significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose transporter 2 (SGLT2) inhibitors compared to patients who received placebo; this risk may be greater with higher doses of INVOKANA. INVOKANA is not indicated for glycemic control in patients with type 1 diabetes mellitus.</paragraph>
                        <paragraph>Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including INVOKANA.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Urinary glucose excretion persists for 3 days after discontinuing INVOKANA
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>];
 
   </content>however, there have been postmarketing reports of ketoacidosis and/or glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors.

  </content>
                        </paragraph>
                        <paragraph>Consider ketone monitoring in patients at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis. If ketoacidosis is suspected, discontinue INVOKANA, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting INVOKANA.</paragraph>
                        <paragraph>Withhold INVOKANA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume INVOKANA when the patient is clinically stable and has resumed oral intake
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue INVOKANA and seek medical attention immediately if signs and symptoms occur.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2a427270-3147-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Lower Limb Amputation</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">An increased risk of lower limb amputations associated with INVOKANA use versus placebo was observed in CANVAS (5.9 vs 2.8 events per 1,000 patient-years) and CANVAS-R (7.5 vs 4.2 events per 1,000 patient-years), two randomized, placebo-controlled trials evaluating adult patients with type 2 diabetes mellitus who had either established cardiovascular disease or were at risk for cardiovascular disease. The risk of lower limb amputations was observed at both the 100 mg and 300 mg once daily dosage regimens. The amputation data for CANVAS and CANVAS-R are shown in Tables 3 and 4, respectively
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].
 
   </content>
                           </content>
                        </paragraph>
                        <paragraph>Amputations of the toe and midfoot (99 out of 140 patients with amputations receiving INVOKANA in the two trials) were the most frequent; however, amputations involving the leg, below and above the knee, were also observed (41 out of 140 patients with amputations receiving INVOKANA in the two trials). Some patients had multiple amputations, some involving both lower limbs.</paragraph>
                        <paragraph>Lower limb infections, gangrene, and diabetic foot ulcers were the most common precipitating medical events leading to the need for an amputation. The risk of amputation was highest in patients with a baseline history of prior amputation, peripheral vascular disease, and neuropathy.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Counsel patients about the importance of routine preventative foot care. Monitor patients receiving INVOKANA for signs and symptoms of infection (including osteomyelitis), new pain or tenderness, sores or ulcers involving the lower limbs, and discontinue INVOKANA if these complications occur.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="2a427270-3148-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Volume Depletion</title>
                     <text>
                        <paragraph>INVOKANA can cause intravascular volume contraction which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. There have been post-marketing reports of acute kidney injury which are likely related to volume depletion, some requiring hospitalizations and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA. Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m
 
  <sup>2</sup>), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before initiating INVOKANA in patients with one or more of these characteristics, assess and correct volume status. Monitor for signs and symptoms of volume depletion after initiating therapy.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="2a427270-3149-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Urosepsis and Pyelonephritis</title>
                     <text>
                        <paragraph>There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving INVOKANA. Treatment with INVOKANA increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="2a427270-314a-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</title>
                     <text>
                        <paragraph>Insulin and insulin secretagogues are known to cause hypoglycemia. INVOKANA may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="2a427270-314b-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Necrotizing Fasciitis of the Perineum (Fournier's Gangrene)</title>
                     <text>
                        <paragraph>Reports of necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA. Cases have been reported in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death.</paragraph>
                        <paragraph>Patients treated with INVOKANA presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue INVOKANA, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="2a427270-314c-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Genital Mycotic Infections</title>
                     <text>
                        <paragraph>INVOKANA increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. Monitor and treat appropriately.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="2a427270-314d-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported with INVOKANA. These reactions generally occurred within hours to days after initiating INVOKANA. If hypersensitivity reactions occur, discontinue use of INVOKANA; treat and monitor until signs and symptoms resolve
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>and
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>,
  
   <linkHtml href="#S6.2">6.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="2a427270-314e-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Bone Fracture</title>
                     <text>
                        <paragraph>An increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in adult patients using INVOKANA in the CANVAS trial
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]
 
  </content>. Consider factors that contribute to fracture risk prior to initiating INVOKANA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="2a427270-314f-bf22-e063-6294a90aaa69"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following important adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Diabetic Ketoacidosis in Patients with Type 1 Diabetes and Other Ketoacidosis
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Lower Limb Amputation
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Volume Depletion
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Urosepsis and Pyelonephritis
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                     <item>Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                     <item>Necrotizing Fasciitis of the Perineum (Fournier's gangrene)
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]
  
   </content>
                     </item>
                     <item>Genital Mycotic Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
  
   </content>
                     </item>
                     <item>Hypersensitivity Reactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]
  
   </content>
                     </item>
                     <item>Bone Fracture
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination (
 
    <linkHtml href="#S6.1">6.1</linkHtml>).

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="2a427270-3150-bf22-e063-6294a90aaa69"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>INVOKANA has been evaluated in clinical trials in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Additionally, INVOKANA has been studied in clinical trials in adult patients with type 2 diabetes mellitus who also have heart failure or chronic kidney disease. The overall safety profile of INVOKANA was consistent across the studied indications.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-3151-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Trials in Adult Patients with Type 2 Diabetes Mellitus</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-3152-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pool of Placebo-Controlled Trials for Glycemic Control</content>
                                    </paragraph>
                                    <paragraph>The data in Table 2 are derived from four 26-week placebo-controlled trials where INVOKANA was used as monotherapy in one trial and as add-on therapy in three trials. These data reflect exposure of 1,667 adult patients to INVOKANA and a mean duration of exposure to INVOKANA of 24 weeks. Patients received INVOKANA 100 mg (N=833), INVOKANA 300 mg (N=834) or placebo (N=646) once daily. The mean age of the population was 56 years and 2% were older than 75 years of age. Fifty percent (50%) of the population was male and 72% were White, 12% were Asian, and 5% were Black or African American. At baseline the population had diabetes for an average of 7.3 years, had a mean HbA
 
  <sub>1C</sub>of 8.0% and 20% had established microvascular complications of diabetes. Baseline renal function was normal or mildly impaired (mean eGFR 88 mL/min/1.73 m
 
  <sup>2</sup>).

 </paragraph>
                                    <paragraph>Table 2 shows common adverse reactions associated with the use of INVOKANA. These adverse reactions were not present at baseline, occurred more commonly on INVOKANA than on placebo, and occurred in at least 2% of patients treated with either INVOKANA 100 mg or INVOKANA 300 mg.</paragraph>
                                    <table width="90%">
                                       <caption>Table 2: Adverse Reactions from Pool of Four 26âWeek Placebo-Controlled Trials Reported in â¥ 2% of INVOKANA-Treated Adult Patients
  
   <footnote ID="K2105">The four placebo-controlled trials included one monotherapy trial and three add-on combination trials with metformin HCl, metformin HCl and sulfonylurea, or metformin HCl and pioglitazone.</footnote>
                                       </caption>
                                       <col width="40%" align="left" valign="bottom"/>
                                       <col width="20%" align="center" valign="bottom"/>
                                       <col width="20%" align="center" valign="bottom"/>
                                       <col width="20%" align="center" valign="bottom"/>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="4">Note: Percentages were weighted by studies. Trial weights were proportional to the harmonic mean of the three treatment sample sizes.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Adverse Reaction</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo 
      <br/>  N=646
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 
      <br/>  100 mg 
      <br/>  N=833
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 
      <br/>  300 mg 
      <br/>  N=834
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Urinary tract infections
    
     <footnote ID="K2167">Urinary tract infections include the following adverse reactions: Urinary tract infection, Cystitis, Kidney infection, and Urosepsis.</footnote>
                                             </td>
                                             <td styleCode="Rrule">3.8%</td>
                                             <td styleCode="Rrule">5.9%</td>
                                             <td styleCode="Rrule">4.4%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased urination
    
     <footnote ID="K2183">Increased urination includes the following adverse reactions: Polyuria, Pollakiuria, Urine output increased, Micturition urgency, and Nocturia.</footnote>
                                             </td>
                                             <td styleCode="Rrule">0.7%</td>
                                             <td styleCode="Rrule">5.1%</td>
                                             <td styleCode="Rrule">4.6%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Thirst
    
     <footnote ID="K2199">Thirst includes the following adverse reactions: Thirst, Dry mouth, and Polydipsia.</footnote>
                                             </td>
                                             <td styleCode="Rrule">0.1%</td>
                                             <td styleCode="Rrule">2.8%</td>
                                             <td styleCode="Rrule">2.4%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Constipation</td>
                                             <td styleCode="Rrule">0.9%</td>
                                             <td styleCode="Rrule">1.8%</td>
                                             <td styleCode="Rrule">2.4%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Nausea</td>
                                             <td styleCode="Rrule">1.6%</td>
                                             <td styleCode="Rrule">2.1%</td>
                                             <td styleCode="Rrule">2.3%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=312</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=425</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=430</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Female genital mycotic infections
    
     <footnote ID="K2262">Female genital mycotic infections include the following adverse reactions: Vulvovaginal candidiasis, Vulvovaginal mycotic infection, Vulvovaginitis, Vaginal infection, Vulvitis, and Genital infection fungal.</footnote>
                                             </td>
                                             <td styleCode="Rrule">2.8%</td>
                                             <td styleCode="Rrule">10.6%</td>
                                             <td styleCode="Rrule">11.6%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Vulvovaginal pruritus</td>
                                             <td styleCode="Rrule">0.0%</td>
                                             <td styleCode="Rrule">1.6%</td>
                                             <td styleCode="Rrule">3.2%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=334</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=408</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">N=404</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Male genital mycotic infections
    
     <footnote ID="K2310">Male genital mycotic infections include the following adverse reactions: Balanitis or Balanoposthitis, Balanitis candida, and Genital infection fungal.</footnote>
                                             </td>
                                             <td styleCode="Rrule">0.7%</td>
                                             <td styleCode="Rrule">4.2%</td>
                                             <td styleCode="Rrule">3.8%</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Abdominal pain was also more commonly reported in patients taking INVOKANA 100 mg (1.8%), 300 mg (1.7%) than in patients taking placebo (0.8%).</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3153-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Placebo-Controlled Trial in Diabetic Nephropathy</content>
                                    </paragraph>
                                    <paragraph>The occurrence of adverse reactions for INVOKANA was evaluated in patients participating in CREDENCE, a trial in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria &gt; 300 mg/day
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>]
 
  </content>. These data reflect exposure of 2,201 adult patients to INVOKANA and a mean duration of exposure to INVOKANA of 137 weeks.

 </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>The rate of lower limb amputations associated with the use of INVOKANA 100 mg relative to placebo was 12.3 vs 11.2 events per 1,000 patient-years, respectively, with 2.6 years mean duration of follow-up.</item>
                                       <item>The incidence of hypotension was 2.8% and 1.5% on INVOKANA 100 mg and placebo, respectively.</item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3154-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pool of Placebo- and Active-Controlled Trials for Glycemic Control and Cardiovascular Outcomes in Adult Patients</content>
                                    </paragraph>
                                    <paragraph>The occurrence of adverse reactions for INVOKANA was evaluated in adult patients participating in placebo- and active-controlled trials and in an integrated analysis of two cardiovascular trials, CANVAS and CANVAS-R.</paragraph>
                                    <paragraph>The types and frequency of common adverse reactions observed in the pool of eight clinical trials (which reflect an exposure of 6,177 adult patients to INVOKANA) were consistent with those listed in Table 2. Percentages were weighted by trials. Trial weights were proportional to the harmonic mean of the three treatment sample sizes. In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.8%, 2.2%, and 2.0% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively) and loss of strength or energy (i.e., asthenia) (0.6%, 0.7%, and 1.1% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively).</paragraph>
                                    <paragraph>In the pool of eight clinical trials, the incidence rate of pancreatitis (acute or chronic) was 0.1%, 0.2%, and 0.1% receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.</paragraph>
                                    <paragraph>In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of adult patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA. Among these patients, 2 patients discontinued INVOKANA. One patient with urticaria had recurrence when INVOKANA was re-initiated.</paragraph>
                                    <paragraph>Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.</paragraph>
                                    <paragraph>Other adverse reactions occurring more frequently on INVOKANA than on comparator were:</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3155-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lower Limb Amputation</content>
                                    </paragraph>
                                    <paragraph>An increased risk of lower limb amputations associated with INVOKANA use versus placebo was observed in CANVAS (5.9 vs 2.8 events per 1,000 patient-years) and CANVAS-R (7.5 vs 4.2 events per 1,000 patient-years), two randomized, placebo-controlled trials evaluating adult patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. Patients in CANVAS and CANVAS-R were followed for an average of 5.7 and 2.1 years, respectively
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]
 
  </content>. The amputation data for CANVAS and CANVAS-R are shown in Tables 3 and 4, respectively
 
  <content styleCode="italics">.</content>
                                    </paragraph>
                                    <table width="90%" ID="table3">
                                       <caption>Table 3: Amputations in the CANVAS Trial in Adults with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease</caption>
                                       <col width="28%" align="left" valign="middle"/>
                                       <col width="18%" align="center" valign="middle"/>
                                       <col width="18%" align="center" valign="middle"/>
                                       <col width="18%" align="center" valign="middle"/>
                                       <col width="18%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Placebo 
     <br/>  N=1,441
    </th>
                                             <th styleCode="Rrule">INVOKANA 
     <br/>  100 mg 
     <br/>  N=1,445
    </th>
                                             <th styleCode="Rrule">INVOKANA 
     <br/>  300 mg 
     <br/>  N=1,441
    </th>
                                             <th styleCode="Rrule">INVOKANA 
     <br/>  (Pooled) 
     <br/>  N=2,886
    </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="5">Note: Incidence is based on the number of patients with at least one amputation, and not the total number of amputation events. A patient's follow-up is calculated from Day 1 to the first amputation event date. Some patients had more than one amputation.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Patients with an amputation, n (%)</td>
                                             <td styleCode="Rrule">22 (1.5)</td>
                                             <td styleCode="Rrule">50 (3.5)</td>
                                             <td styleCode="Rrule">45 (3.1)</td>
                                             <td styleCode="Rrule">95 (3.3)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Total amputations</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">83</td>
                                             <td styleCode="Rrule">79</td>
                                             <td styleCode="Rrule">162</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Amputation incidence rate 
     <br/>  (per 1,000 patient-years)
    </td>
                                             <td styleCode="Rrule">2.8</td>
                                             <td styleCode="Rrule">6.2</td>
                                             <td styleCode="Rrule">5.5</td>
                                             <td styleCode="Rrule">5.9</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Hazard Ratio (95% CI)</td>
                                             <td styleCode="Rrule">--</td>
                                             <td styleCode="Rrule">2.24 (1.36, 3.69)</td>
                                             <td styleCode="Rrule">2.01 (1.20, 3.34)</td>
                                             <td styleCode="Rrule">2.12 (1.34, 3.38)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="90%" ID="tab4">
                                       <caption>Table 4: Amputations in the CANVAS-R Trial in Adults with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease</caption>
                                       <col width="40%" align="left" valign="middle"/>
                                       <col width="30%" align="center" valign="middle"/>
                                       <col width="30%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Placebo 
     <br/>  N=2,903
    </th>
                                             <th styleCode="Rrule">INVOKANA 
     <br/>  100 mg 
     <br/>  (with up-titration to 300 mg) 
     <br/>  N=2,904
    </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="3">Note: Incidence is based on the number of patients with at least one amputation, and not the total number of amputation events. A patient's follow-up is calculated from Day 1 to the first amputation event date. Some patients had more than one amputation.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Patients with an amputation, n (%)</td>
                                             <td styleCode="Rrule">25 (0.9)</td>
                                             <td styleCode="Rrule">45 (1.5)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Total amputations</td>
                                             <td styleCode="Rrule">36</td>
                                             <td styleCode="Rrule">59</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Amputation incidence rate 
     <br/>  (per 1,000 patient-years)
    </td>
                                             <td styleCode="Rrule">4.2</td>
                                             <td styleCode="Rrule">7.5</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Hazard Ratio (95% CI)</td>
                                             <td styleCode="Rrule">--</td>
                                             <td styleCode="Rrule">1.80 (1.10, 2.93)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3156-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Cell Carcinoma</content>
                                    </paragraph>
                                    <paragraph>In the CANVAS trial in adults (mean duration of follow-up of 5.7 years)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]
 
  </content>, the incidence of renal cell carcinoma was 0.15% (2/1,331) and 0.29% (8/2,716) for placebo and INVOKANA, respectively, excluding patients with less than 6 months of follow-up, less than 90 days of treatment, or a history of renal cell carcinoma. A causal relationship to INVOKANA could not be established due to the limited number of cases.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3157-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Volume Depletion-Related Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume. In clinical trials for glycemic control, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration). An increased incidence was observed in adult patients on the 300 mg dose. The three factors associated with the largest increase in volume depletion-related adverse reactions in these trials were the use of loop diuretics, moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m
 
  <sup>2</sup>), and age 75 years and older (Table 5)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>and
  
   <linkHtml href="#S8.6">8.6)</linkHtml>]
 
  </content>.

 </paragraph>
                                    <table width="90%">
                                       <caption>Table 5: Proportion of Adult Patients with at Least One Volume Depletion-Related Adverse Reaction (Pooled Results from 8 Clinical Trials for Glycemic Control)</caption>
                                       <col width="33%" align="left" valign="bottom"/>
                                       <col width="22%" align="center" valign="bottom"/>
                                       <col width="23%" align="center" valign="bottom"/>
                                       <col width="22%" align="center" valign="bottom"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Baseline Characteristic</th>
                                             <th styleCode="Rrule">Comparator Group
    
     <footnote ID="K2713">Includes placebo and active-comparator groups</footnote>
                                                <br/>  %
   
    </th>
                                             <th styleCode="Rrule">INVOKANA 100 mg 
     <br/>  %
    </th>
                                             <th styleCode="Rrule">INVOKANA 300 mg 
     <br/>  %
    </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall population</td>
                                             <td styleCode="Rrule">1.5%</td>
                                             <td styleCode="Rrule">2.3%</td>
                                             <td styleCode="Rrule">3.4%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">75 years of age and older
    
     <footnote ID="t4f2">Patients could have more than 1 of the listed risk factors</footnote>
                                             </td>
                                             <td styleCode="Rrule">2.6%</td>
                                             <td styleCode="Rrule">4.9%</td>
                                             <td styleCode="Rrule">8.7%</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">eGFR less than 60 mL/min/1.73 m
    
     <sup>2</sup>
                                                <footnoteRef IDREF="t4f2"/>
                                             </td>
                                             <td styleCode="Rrule">2.5%</td>
                                             <td styleCode="Rrule">4.7%</td>
                                             <td styleCode="Rrule">8.1%</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Use of loop diuretic
    
     <footnoteRef IDREF="t4f2"/>
                                             </td>
                                             <td styleCode="Rrule">4.7%</td>
                                             <td styleCode="Rrule">3.2%</td>
                                             <td styleCode="Rrule">8.8%</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3158-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Falls</content>
                                    </paragraph>
                                    <paragraph>In a pool of nine clinical trials in adults with mean duration of exposure to INVOKANA of 85 weeks, the proportion of patients who experienced falls was 1.3%, 1.5%, and 2.1% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. The higher risk of falls for patients treated with INVOKANA was observed within the first few weeks of treatment.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3159-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Genital Mycotic Infections</content>
                                    </paragraph>
                                    <paragraph>In the pool of four placebo-controlled clinical trials in adults for glycemic control, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 2.8%, 10.6%, and 11.6% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections on INVOKANA. Female patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrence and require treatment with oral or topical antifungal agents and anti-microbial agents. In females, discontinuation due to genital mycotic infections occurred in 0% and 0.7% of patients treated with placebo and INVOKANA, respectively.</paragraph>
                                    <paragraph>In the pool of four placebo-controlled clinical trials in adults, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.7%, 4.2%, and 3.8% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Male genital mycotic infections occurred more commonly in uncircumcised males and in males with a prior history of balanitis or balanoposthitis. Male patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrent infections (22% on INVOKANA versus none on placebo) and require treatment with oral or topical antifungal agents and anti-microbial agents than patients on comparators. In males, discontinuations due to genital mycotic infections occurred in 0% and 0.5% of patients treated with placebo and INVOKANA, respectively.</paragraph>
                                    <paragraph>In the pooled analysis of 8 randomized trials in adults evaluating glycemic control, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-315a-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hypoglycemia</content>
                                    </paragraph>
                                    <paragraph>In all glycemic control trials, hypoglycemia was defined as any event regardless of symptoms, where biochemical hypoglycemia was documented (any glucose value below or equal to 70 mg/dL). Severe hypoglycemia was defined as an event consistent with hypoglycemia where the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained). In individual clinical trials of glycemic control in adults
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]
 
  </content>, episodes of hypoglycemia occurred at a higher rate when INVOKANA was co-administered with insulin or sulfonylureas (Table 6).

 </paragraph>
                                    <table width="90%">
                                       <caption>Table 6: Incidence of Hypoglycemia
  
   <footnote ID="K2859">Number of patients experiencing at least one event of hypoglycemia based on either biochemically documented episodes or severe hypoglycemic events in the intent-to-treat population</footnote>in Randomized Clinical Trials of Glycemic Control in Adults
 
  </caption>
                                       <col width="30%" align="left" valign="bottom"/>
                                       <col width="20%" align="center" valign="bottom"/>
                                       <col width="25%" align="center" valign="bottom"/>
                                       <col width="25%" align="center" valign="bottom"/>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Monotherapy 
      <br/>  (26 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo 
      <br/>  (N=192)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg 
      <br/>  (N=195)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg 
      <br/>  (N=197)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">5 (2.6)</td>
                                             <td styleCode="Rrule">7 (3.6)</td>
                                             <td styleCode="Rrule">6 (3.0)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Metformin HCl 
      <br/>  (26 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo + Metformin HCl 
      <br/>  (N=183)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg + Metformin HCl 
      <br/>  (N=368)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Metformin HCl 
      <br/>  (N=367)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">3 (1.6)</td>
                                             <td styleCode="Rrule">16 (4.3)</td>
                                             <td styleCode="Rrule">17 (4.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Severe [N (%)]
    
     <footnote ID="t6f2">Severe episodes of hypoglycemia were defined as those where the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained)</footnote>
                                             </td>
                                             <td styleCode="Rrule">0 (0)</td>
                                             <td styleCode="Rrule">1 (0.3)</td>
                                             <td styleCode="Rrule">1 (0.3)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Metformin HCl 
      <br/>  (52 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Glimepiride + Metformin HCl 
      <br/>  (N=482)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg + Metformin HCl 
      <br/>  (N=483)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Metformin HCl 
      <br/>  (N=485)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">165 (34.2)</td>
                                             <td styleCode="Rrule">27 (5.6)</td>
                                             <td styleCode="Rrule">24 (4.9)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Severe [N (%)]
    
     <footnoteRef IDREF="t6f2"/>
                                             </td>
                                             <td styleCode="Rrule">15 (3.1)</td>
                                             <td styleCode="Rrule">2 (0.4)</td>
                                             <td styleCode="Rrule">3 (0.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Sulfonylurea 
      <br/>  (18 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo + Sulfonylurea 
      <br/>  (N=69)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg + Sulfonylurea 
      <br/>  (N=74)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Sulfonylurea 
      <br/>  (N=72)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">4 (5.8)</td>
                                             <td styleCode="Rrule">3 (4.1)</td>
                                             <td styleCode="Rrule">9 (12.5)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Metformin HCl + Sulfonylurea 
      <br/>  (26 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo + Metformin HCl + Sulfonylurea 
      <br/>  (N=156)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg + Metformin HCl + Sulfonylurea 
      <br/>  (N=157)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Metformin HCl + Sulfonylurea 
      <br/>  (N=156)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">24 (15.4)</td>
                                             <td styleCode="Rrule">43 (27.4)</td>
                                             <td styleCode="Rrule">47 (30.1)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Severe [N (%)]
    
     <footnoteRef IDREF="t6f2"/>
                                             </td>
                                             <td styleCode="Rrule">1 (0.6)</td>
                                             <td styleCode="Rrule">1 (0.6)</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Metformin HCl + Sulfonylurea 
      <br/>  (52 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Sitagliptin + Metformin HCl + Sulfonylurea 
      <br/>  (N=378)
     </content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Metformin HCl + Sulfonylurea 
      <br/>  (N=377)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">154 (40.7)</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">163 (43.2)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Severe [N (%)]
    
     <footnoteRef IDREF="t6f2"/>
                                             </td>
                                             <td styleCode="Rrule">13 (3.4)</td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">15 (4.0)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Metformin HCl + Pioglitazone 
      <br/>  (26 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo + Metformin HCl + Pioglitazone 
      <br/>  (N=115)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg + Metformin HCl + Pioglitazone 
      <br/>  (N=113)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg + Metformin HCl + Pioglitazone 
      <br/>  (N=114)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">3 (2.6)</td>
                                             <td styleCode="Rrule">3 (2.7)</td>
                                             <td styleCode="Rrule">6 (5.3)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">In Combination with Insulin 
      <br/>  (18 weeks)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Placebo 
      <br/>  (N=565)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 100 mg 
      <br/>  (N=566)
     </content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">INVOKANA 300 mg 
      <br/>  (N=587)
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Overall [N (%)]</td>
                                             <td styleCode="Rrule">208 (36.8)</td>
                                             <td styleCode="Rrule">279 (49.3)</td>
                                             <td styleCode="Rrule">285 (48.6)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Severe [N (%)]
    
     <footnoteRef IDREF="t6f2"/>
                                             </td>
                                             <td styleCode="Rrule">14 (2.5)</td>
                                             <td styleCode="Rrule">10 (1.8)</td>
                                             <td styleCode="Rrule">16 (2.7)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-315b-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bone Fracture</content>
                                    </paragraph>
                                    <paragraph>In the CANVAS trial in adults
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]
 
  </content>, the incidence rates of all adjudicated bone fracture were 1.09, 1.59, and 1.79 events per 100 patient-years of follow-up to placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. The fracture imbalance was observed within the first 26 weeks of therapy and remained through the end of the trial. Fractures were more likely to be low trauma (e.g., fall from no more than standing height), and affect the distal portion of upper and lower extremities.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-315c-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory and Imaging Tests</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-315d-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Increases in Serum Creatinine and Decreases in eGFR</content>
                                    </paragraph>
                                    <paragraph>Initiation of INVOKANA causes an increase in serum creatinine and decrease in estimated GFR. In adult patients with moderate renal impairment, the increase in serum creatinine generally does not exceed 0.2 mg/dL, occurs within the first 6 weeks of starting therapy, and then stabilizes. Increases that do not fit this pattern should prompt further evaluation to exclude the possibility of acute kidney injury
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]
 
  </content>. The acute effect on eGFR reverses after treatment discontinuation suggesting acute hemodynamic changes may play a role in the renal function changes observed with INVOKANA.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-315e-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Increases in Serum Potassium</content>
                                    </paragraph>
                                    <paragraph>In a pooled population of adult patients (N=723) in glycemic control trials with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m
 
  <sup>2</sup>), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Severe elevations (greater than or equal to 6.5 mEq/L) occurred in 0.4% of patients treated with placebo, no patients treated with INVOKANA 100 mg, and 1.3% of patients treated with INVOKANA 300 mg.

 </paragraph>
                                    <paragraph>In these patients, increases in potassium were more commonly seen in those with elevated potassium at baseline. Among patients with moderate renal impairment, approximately 84% were taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, angiotensin-converting-enzyme inhibitors, and angiotensin-receptor blockers
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]
 
  </content>.

 </paragraph>
                                    <paragraph>In CREDENCE, no difference in serum potassium, no increase in adverse events of hyperkalemia, and no increase in absolute (&gt; 6.5 mEq/L) or relative (&gt; upper limit of normal and &gt; 15% increase from baseline) increases in serum potassium were observed in adults treated with INVOKANA 100 mg relative to placebo.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-315f-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Increases in Low-Density Lipoprotein Cholesterol (LDL-C) and non-High-Density Lipoprotein Cholesterol (non-HDL-C)</content>
                                    </paragraph>
                                    <paragraph>In the pool of four glycemic control placebo-controlled trials in adults, dose-related increases in LDL-C with INVOKANA were observed. Mean changes (percent changes) from baseline in LDL-C relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with INVOKANA 100 mg and INVOKANA 300 mg, respectively. The mean baseline LDL-C levels were 104 to 110 mg/dL across treatment groups.</paragraph>
                                    <paragraph>Dose-related increases in non-HDL-C with INVOKANA were observed in adults. Mean changes (percent changes) from baseline in non-HDL-C relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with INVOKANA 100 mg and 300 mg, respectively. The mean baseline non-HDL-C levels were 140 to 147 mg/dL across treatment groups.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3160-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Increases in Hemoglobin</content>
                                    </paragraph>
                                    <paragraph>In the pool of four placebo-controlled trials of glycemic control in adults, mean changes (percent changes) from baseline in hemoglobin were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with INVOKANA 100 mg, and 0.51 g/dL (3.8%) with INVOKANA 300 mg. The mean baseline hemoglobin value was approximately 14.1 g/dL across treatment groups. At the end of treatment, 0.8%, 4.0%, and 2.7% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively, had hemoglobin above the upper limit of normal.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3161-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreases in Bone Mineral Density</content>
                                    </paragraph>
                                    <paragraph>Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry in a clinical trial of 714 older adults (mean age 64 years)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]
 
  </content>. At 2 years, adult patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively. Additionally, placebo-adjusted BMD declines were 0.1% at the femoral neck for both INVOKANA doses and 0.4% at the distal forearm for patients randomized to INVOKANA 300 mg. The placebo-adjusted change at the distal forearm for patients randomized to INVOKANA 100 mg was 0%.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3162-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Trial in Pediatric Patients Aged 10 Years and Older with Type 2 Diabetes Mellitus</content>
                              </paragraph>
                              <paragraph>INVOKANA was administered to 84 pediatric patients in a double-blind, placebo-controlled trial of 171 pediatric patients aged 10 to 17 years with a mean exposure to INVOKANA of 48.3 weeks
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]
 
  </content>. At baseline, background therapies included metformin monotherapy (46%), metformin and insulin (29%), diet and exercise only (14%), and insulin monotherapy (11%). Approximately 42% were Asian, 42% were White, 11% were Black or African American, 5% were American Indian/Alaska Native, and 36% identified as Hispanic or Latino ethnicity. The mean baseline eGFR was 157.3 mL/min/1.73 m
 
  <sup>2</sup>, and approximately 16% (24/151) of the trial population with measurements had microalbuminuria or macroalbuminuria. The safety profile of pediatric patients treated with INVOKANA was similar to that observed in adults with type 2 diabetes mellitus.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="2a427270-3163-bf22-e063-6294a90aaa69"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Additional adverse reactions have been identified during post-approval use of INVOKANA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Nutrition</content>
                           <br/>
                           <content styleCode="italics">Ketoacidosis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal and Urinary</content>
                           <br/>
                           <content styleCode="italics">Acute Kidney Injury</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System</content>
                           <br/>
                           <content styleCode="italics">Anaphylaxis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Skin and Subcutaneous Tissue</content>
                           <br/>
                           <content styleCode="italics">Angioedema</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Infections</content>
                           <br/>
                           <content styleCode="italics">Urosepsis and Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's gangrene)</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="2a427270-3164-bf22-e063-6294a90aaa69"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <table width="95%" ID="table7">
                     <caption>Table 7: Clinically Significant Drug Interactions with INVOKANA</caption>
                     <col width="20%" align="right" valign="top"/>
                     <col width="80%" align="left" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">UGT Enzyme Inducers</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">For patients with eGFR 60 mL/min/1.73 m
    
     <sup>2</sup>or greater, if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily. The total daily dosage may be increased to 300 mg daily in patients currently tolerating INVOKANA 200 mg daily who require additional glycemic control. 
     <br/>  For patients with eGFR less than 60 mL/min/1.73 m
    
     <sup>2</sup>, if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily. Consider adding another antihyperglycemic agent in patients who require additional glycemic control
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>and
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Rrule">Rifampin, phenytoin, phenobarbital, ritonavir</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Insulin or Insulin Secretagogues</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use may require a lower dosage of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Digoxin</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Canagliflozin increases digoxin exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Monitor patients taking INVOKANA with concomitant digoxin for a need to adjust the dosage of digoxin.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Lithium</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Monitor serum lithium concentration more frequently during INVOKANA initiation and dosage changes.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">
                              <content styleCode="bold">Drug/Laboratory Test Interference</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">Â Â 
    
     <content styleCode="bold">
                                 <content styleCode="italics">Positive Urine Glucose Test</content>
                              </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">SGLT2 inhibitors increase urinary glucose excretion which will lead to positive urine glucose tests.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" align="left" styleCode="Lrule Rrule">Â Â 
    
     <content styleCode="bold">
                                 <content styleCode="italics">Interference with 1,5-anhydroglucitol (1,5-AG) Assay</content>
                              </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Monitoring glycemic control with 1,5-AG assay is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for information on drug interactions and interference of INVOKANA with laboratory tests (
 
    <linkHtml href="#S7">7</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="2a427270-3165-bf22-e063-6294a90aaa69"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: Advise females of the potential risk to a fetus especially during the second and third trimesters (
  
     <linkHtml href="#S8.1">8.1</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Lactation</content>: Not recommended when breastfeeding (
  
     <linkHtml href="#S8.2">8.2</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Geriatrics</content>: Higher incidence of adverse reactions related to reduced intravascular volume (
  
     <linkHtml href="#S8.5">8.5</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Renal Impairment</content>: Higher incidence of adverse reactions related to hypotension and renal function (
  
     <linkHtml href="#S8.6">8.6</linkHtml>).
 
    </item>
                           <item>
                              <content styleCode="underline">Hepatic Impairment</content>: Not recommended in patients with severe hepatic impairment (
  
     <linkHtml href="#S8.7">8.7</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="2a427270-3166-bf22-e063-6294a90aaa69"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-3167-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on juvenile animal data showing adverse renal effects, INVOKANA is not recommended during the second and third trimesters of pregnancy.</paragraph>
                              <paragraph>Limited data with INVOKANA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#CC">Clinical Considerations</linkHtml>].
 
  </content>
                              </paragraph>
                              <paragraph>In juvenile animal studies, adverse renal pelvic and tubule dilatations that were not reversible were observed in rats when canagliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy, at an exposure 0.5-times the 300 mg clinical dose, based on AUC.</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6â10% in women with pre-gestational diabetes with a HbA
 
  <sub>1C</sub>&gt;7 and has been reported to be as high as 20â25% in women with a HbA
 
  <sub>1C</sub>&gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2â4% and 15â20%, respectively.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="2a427270-3168-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-3169-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-316a-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Canagliflozin dosed directly to juvenile rats from postnatal day (PND) 21 until PND 90 at doses of 4, 20, 65, or 100 mg/kg increased kidney weights and dose dependently increased the incidence and severity of renal pelvic and tubular dilatation at all doses tested. Exposure at the lowest dose was greater than or equal to 0.5-times the 300 mg clinical dose, based on AUC. These outcomes occurred with drug exposure during periods of renal development in rats that correspond to the late second and third trimester of human renal development. The renal pelvic dilatations observed in juvenile animals did not fully reverse within a 1-month recovery period.</paragraph>
                                    <paragraph>In embryo-fetal development studies in rats and rabbits, canagliflozin was administered for intervals coinciding with the first trimester period of organogenesis in humans. No developmental toxicities independent of maternal toxicity were observed when canagliflozin was administered at doses up to 100 mg/kg in pregnant rats and 160 mg/kg in pregnant rabbits during embryonic organogenesis or during a study in which maternal rats were dosed from gestation day (GD) 6 through PND 21, yielding exposures up to approximately 19-times the 300 mg clinical dose, based on AUC.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="2a427270-316b-bf22-e063-6294a90aaa69"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-316c-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of INVOKANA in human milk, the effects on the breastfed infant, or the effects on milk production. Canagliflozin is present in the milk of lactating rats
 
  <content styleCode="italics">[see
  
   <linkHtml href="#data">Data</linkHtml>]
 
  </content>. Since human kidney maturation occurs
 
  <content styleCode="italics">in utero</content>and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney.

 </paragraph>
                              <paragraph>Because of the potential for serious adverse reactions in a breastfed infant, advise women that use of INVOKANA is not recommended while breastfeeding.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="2a427270-316d-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-316e-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Radiolabeled canagliflozin administered to lactating rats on day 13 post-partum was present at a milk/plasma ratio of 1.40, indicating that canagliflozin and its metabolites are transferred into milk at a concentration comparable to that in plasma. Juvenile rats directly exposed to canagliflozin showed a risk to the developing kidney (renal pelvic and tubular dilatations) during maturation.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="2a427270-316f-bf22-e063-6294a90aaa69"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of INVOKANA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients aged 10 years and older.</paragraph>
                        <paragraph>Use of INVOKANA for this indication is supported by evidence from a 52-week double-blind, placebo-controlled trial in 171 pediatric patients aged 10 to 17 years with type 2 diabetes mellitus and in a pediatric pharmacokinetic study
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>and
  
   <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]
 
  </content>. The safety profile of pediatric patients treated with INVOKANA was similar to that observed in adults with type 2 diabetes mellitus.

 </paragraph>
                        <paragraph>The safety and effectiveness of INVOKANA for glycemic control in patients with type 2 diabetes have not been established in pediatric patients under 10 years of age.</paragraph>
                        <paragraph>The safety and effectiveness of INVOKANA have not been established in pediatric patients to reduce the risk of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in patients with type 2 diabetes mellitus and established cardiovascular disease (CVD).</item>
                           <item>end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="2a427270-3170-bf22-e063-6294a90aaa69"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In 13 clinical trials of INVOKANA, 2,294 patients 65 years and older, and 351 patients 75 years and older were exposed to INVOKANA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Patients 65 years and older had a higher incidence of adverse reactions related to reduced intravascular volume with INVOKANA (such as hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration), particularly with the 300 mg daily dose, compared to younger patients; a more prominent increase in the incidence was seen in patients who were 75 years and older
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>and
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].
 
  </content>Smaller reductions in HbA
 
  <sub>1C</sub>with INVOKANA relative to placebo were seen in older (65 years and older; -0.61% with INVOKANA 100 mg and -0.74% with INVOKANA 300 mg relative to placebo) compared to younger patients (-0.72% with INVOKANA 100 mg and -0.87% with INVOKANA 300 mg relative to placebo).

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="2a427270-3171-bf22-e063-6294a90aaa69"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The efficacy and safety of INVOKANA for glycemic control were evaluated in a trial that included adult patients with moderate renal impairment (eGFR 30 to less than 50 mL/min/1.73 m
 
  <sup>2</sup>)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]
 
  </content>. These patients had less overall glycemic efficacy, and patients treated with 300 mg per day had increases in serum potassium, which were transient and similar by the end of the trial. Patients with renal impairment using INVOKANA for glycemic control may also be more likely to experience hypotension and may be at higher risk for acute kidney injury
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Efficacy and safety trials with INVOKANA did not enroll adult patients with ESKD on dialysis or patients with an eGFR less than 30 mL/min/1.73 m
 
  <sup>2</sup>
                           <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="2a427270-3172-bf22-e063-6294a90aaa69"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. The use of INVOKANA has not been studied in patients with severe hepatic impairment and is therefore not recommended
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="2a427270-3173-bf22-e063-6294a90aaa69"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of an overdose, contact the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. It is also reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient's clinical status. Canagliflozin was negligibly removed during a 4-hour hemodialysis session. Canagliflozin is not expected to be dialyzable by peritoneal dialysis.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="2a427270-3174-bf22-e063-6294a90aaa69"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>INVOKANA
 
  <sup>Â®</sup>(canagliflozin) contains canagliflozin, an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1
 
  <content styleCode="italics">S</content>)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and its molecular formula and weight are C
 
  <sub>24</sub>H
 
  <sub>25</sub>FO
 
  <sub>5</sub>Sâ1/2 H
 
  <sub>2</sub>O and 453.53, respectively. The structural formula for canagliflozin is:

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Canagliflozin is practically insoluble in aqueous media from pH 1.1 to 12.9.</paragraph>
                  <paragraph>INVOKANA is supplied as film-coated tablets for oral administration, containing 102 and 306 mg of canagliflozin in each tablet strength, corresponding to 100 mg and 300 mg of canagliflozin (anhydrous), respectively.</paragraph>
                  <paragraph>Inactive ingredients of the core tablet are croscarmellose sodium (E468), hydroxypropyl cellulose (E463), lactose anhydrous, magnesium stearate (E572), and microcrystalline cellulose (E460[i]). The magnesium stearate is vegetable-sourced. The tablets are finished with a commercially available film-coating consisting of the following excipients: iron oxide yellow (E172) (100 mg tablet only), macrogol/PEG3350 (E1521), polyvinyl alcohol (E1203) (partially hydrolyzed), talc (E553b), and titanium dioxide (E171).</paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="invokana-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="2a427270-3175-bf22-e063-6294a90aaa69"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S12.1">
                     <id root="2a427270-3176-bf22-e063-6294a90aaa69"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT
 
  <sub>G</sub>), and thereby increases urinary glucose excretion (UGE).

 </paragraph>
                        <paragraph>Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="2a427270-3177-bf22-e063-6294a90aaa69"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Following single and multiple oral doses of canagliflozin in adult patients with type 2 diabetes, dose-dependent decreases in RT
 
  <sub>G</sub>and increases in urinary glucose excretion were observed. From a starting RT
 
  <sub>G</sub>value of approximately 240 mg/dL, canagliflozin at 100 mg and 300 mg once daily suppressed RT
 
  <sub>G</sub>throughout the 24-hour period. Data from single oral doses of canagliflozin in healthy volunteers indicate that, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for doses up to 300 mg once daily. Maximal suppression of mean RT
 
  <sub>G</sub>over the 24-hour period was seen with the 300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 diabetes in Phase 1 trials. The reductions in RT
 
  <sub>G</sub>led to increases in mean UGE of approximately 100 g/day in patients with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin. In patients with type 2 diabetes given 100 to 300 mg once daily over a 16-day dosing period, reductions in RT
 
  <sub>G</sub>and increases in urinary glucose excretion were observed over the dosing period. In this trial, plasma glucose declined in a dose-dependent fashion within the first day of dosing. In single-dose trials in healthy and type 2 diabetic patients, treatment with canagliflozin 300 mg before a mixed-meal delayed intestinal glucose absorption and reduced postprandial glucose.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-3178-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>In a randomized, double-blind, placebo-controlled, active-comparator, 4-way crossover trial, 60 healthy adult subjects were administered a single oral dose of canagliflozin 300 mg, canagliflozin 1,200 mg (4 times the maximum recommended dose), moxifloxacin, and placebo. No meaningful changes in QTc interval were observed with either the recommended dose of 300 mg or the 1,200 mg dose.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="2a427270-3179-bf22-e063-6294a90aaa69"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T
 
  <sub>max</sub>) of canagliflozin occurs within 1 to 2 hours post-dose. Plasma C
 
  <sub>max</sub>and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. The apparent terminal half-life (t
 
  <sub>1/2</sub>) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively. Steady-state was reached after 4 to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg. Canagliflozin does not exhibit time-dependent pharmacokinetics and accumulated in plasma up to 36% following multiple doses of 100 mg and 300 mg.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-317a-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The mean absolute oral bioavailability of canagliflozin is approximately 65%. Co-administration of a high-fat meal with canagliflozin had no effect on the pharmacokinetics of canagliflozin; therefore, INVOKANA may be taken with or without food. However, based on the potential to reduce postprandial plasma glucose excursions due to delayed intestinal glucose absorption, it is recommended that INVOKANA be taken before the first meal of the day
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-317b-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean steady-state volume of distribution of canagliflozin following a single intravenous infusion in healthy subjects was 83.5 L, suggesting extensive tissue distribution. Canagliflozin is extensively bound to proteins in plasma (99%), mainly to albumin. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-317c-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">O</content>-glucuronidation is the major metabolic elimination pathway for canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive
 
  <content styleCode="italics">O</content>-glucuronide metabolites.

 </paragraph>
                              <paragraph>CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-317d-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Excretion</content>
                              </paragraph>
                              <paragraph>Following administration of a single oral [
 
  <sup>14</sup>C] canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in feces as canagliflozin, a hydroxylated metabolite, and an
 
  <content styleCode="italics">O</content>-glucuronide metabolite, respectively. Enterohepatic circulation of canagliflozin was negligible.

 </paragraph>
                              <paragraph>Approximately 33% of the administered radioactive dose was excreted in urine, mainly as
 
  <content styleCode="italics">O</content>-glucuronide metabolites (30.5%). Less than 1% of the dose was excreted as unchanged canagliflozin in urine. Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

 </paragraph>
                              <paragraph>Mean systemic clearance of canagliflozin was approximately 192 mL/min in healthy subjects following intravenous administration.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-317e-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-317f-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics and pharmacodynamics of canagliflozin were investigated in pediatric patients aged 10 years and older with type 2 diabetes mellitus. Oral administration of canagliflozin at 100 mg and 300 mg resulted in exposures and responses consistent with those found in adult patients.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3180-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>A single-dose, open-label trial evaluated the pharmacokinetics of canagliflozin 200 mg in adult subjects with varying degrees of renal impairment (classified using the MDRD-eGFR formula) compared to healthy subjects.</paragraph>
                                    <paragraph>Renal impairment did not affect the C
 
  <sub>max</sub>of canagliflozin. Compared to healthy adult subjects (N=3; eGFR greater than or equal to 90 mL/min/1.73 m
 
  <sup>2</sup>), plasma AUC of canagliflozin was increased by approximately 15%, 29%, and 53% in subjects with mild (N=10), moderate (N=9), and severe (N=10) renal impairment, respectively, (eGFR 60 to less than 90, 30 to less than 60, and 15 to less than 30 mL/min/1.73 m
 
  <sup>2</sup>, respectively), but was similar for ESKD (N=8) subjects and healthy subjects.

 </paragraph>
                                    <paragraph>Increases in canagliflozin AUC of this magnitude are not considered clinically relevant. The glucose lowering pharmacodynamic response to canagliflozin declines with increasing severity of renal impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>and
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                                    <paragraph>Canagliflozin was negligibly removed by hemodialysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3181-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Relative to adult subjects with normal hepatic function, the geometric mean ratios for C
 
  <sub>max</sub>and AUC
 
  <sub>â</sub>of canagliflozin were 107% and 110%, respectively, in subjects with Child-Pugh class A (mild hepatic impairment) and 96% and 111%, respectively, in subjects with Child-Pugh class B (moderate hepatic impairment) following administration of a single 300 mg dose of canagliflozin.

 </paragraph>
                                    <paragraph>These differences are not considered to be clinically meaningful. There is no clinical experience in adult patients with Child-Pugh class C (severe) hepatic impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3182-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pharmacokinetic Effects of Age, Body Mass Index (BMI)/Weight, Gender and Race</content>
                                    </paragraph>
                                    <paragraph>Based on the population PK analysis with data collected from 1,526 adult subjects, age, body mass index (BMI)/weight, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of canagliflozin
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3183-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="2a427270-3184-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Assessment of Drug Interactions</content>
                                    </paragraph>
                                    <paragraph>Canagliflozin did not induce CYP450 enzyme expression (3A4, 2C9, 2C19, 2B6, and 1A2) in cultured human hepatocytes. Canagliflozin did not inhibit the CYP450 isoenzymes (1A2, 2A6, 2C19, 2D6, or 2E1) and weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on
 
  <content styleCode="italics">in vitro</content>studies with human hepatic microsomes. Canagliflozin is a weak inhibitor of P-gp.

 </paragraph>
                                    <paragraph>Canagliflozin is also a substrate of drug transporters P-glycoprotein (P-gp) and MRP2.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2a427270-3185-bf22-e063-6294a90aaa69"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vivo Assessment of Drug Interactions</content>
                                    </paragraph>
                                    <table width="90%">
                                       <caption>Table 8: Effect of CoâAdministered Drugs on Systemic Exposures of Canagliflozin</caption>
                                       <col width="25%" align="left" valign="middle"/>
                                       <col width="18%" align="center" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="center" styleCode="Lrule Rrule">Co-Administered Drug</th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Co-Administered Drug
    
     <footnote ID="t7f1">Single dose unless otherwise noted</footnote>
                                             </th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Canagliflozin
    
     <footnoteRef IDREF="t7f1"/>
                                             </th>
                                             <th colspan="2" styleCode="Botrule Rrule">Geometric Mean Ratio 
     <br/>  (Ratio With/Without Co-Administered Drug) 
     <br/>  No Effect = 1.0
    </th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule">AUC
    
     <footnote ID="K4623">AUC
                 inf for drugs given as a single dose and AUC
                 24h for drugs given as multiple doses
                </footnote>
                                                <br/>  (90% CI)
   
    </th>
                                             <th styleCode="Rrule">C
    
     <sub>max</sub>
                                                <br/>  (90% CI)
   
    </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="5">QD = once daily; BID = twice daily</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule">
                                                <content styleCode="bold">See</content>
                                                <content styleCode="bold">
                                                   <content styleCode="italics">
                                                      <linkHtml href="#S7">Drug Interactions (7)</linkHtml>
                                                   </content>
                                                </content>
                                                <content styleCode="bold">for the clinical relevance of the following:</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rifampin</td>
                                             <td styleCode="Rrule">600 mg QD for 8 days</td>
                                             <td styleCode="Rrule">300 mg</td>
                                             <td styleCode="Rrule">0.49 
     <br/>  (0.44; 0.54)
    </td>
                                             <td styleCode="Rrule">0.72 
     <br/>  (0.61; 0.84)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule">
                                                <content styleCode="bold">No dose adjustments of INVOKANA required for the following:</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Cyclosporine</td>
                                             <td styleCode="Rrule">400 mg</td>
                                             <td styleCode="Rrule">300 mg QD for 8 days</td>
                                             <td styleCode="Rrule">1.23 
     <br/>  (1.19; 1.27)
    </td>
                                             <td styleCode="Rrule">1.01 
     <br/>  (0.91; 1.11)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Ethinyl estradiol and levonorgestrel</td>
                                             <td styleCode="Rrule">0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel</td>
                                             <td styleCode="Rrule">200 mg QD for 6 days</td>
                                             <td styleCode="Rrule">0.91 
     <br/>  (0.88; 0.94)
    </td>
                                             <td styleCode="Rrule">0.92 
     <br/>  (0.84; 0.99)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Hydrochlorothiazide</td>
                                             <td styleCode="Rrule">25 mg QD for 35 days</td>
                                             <td styleCode="Rrule">300 mg QD for 7 days</td>
                                             <td styleCode="Rrule">1.12 
     <br/>  (1.08; 1.17)
    </td>
                                             <td styleCode="Rrule">1.15 
     <br/>  (1.06; 1.25)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Metformin HCl</td>
                                             <td styleCode="Rrule">2,000 mg</td>
                                             <td styleCode="Rrule">300 mg QD for 8 days</td>
                                             <td styleCode="Rrule">1.10 
     <br/>  (1.05; 1.15)
    </td>
                                             <td styleCode="Rrule">1.05 
     <br/>  (0.96; 1.16)
    </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Probenecid</td>
                                             <td styleCode="Rrule">500 mg BID for 3 days</td>
                                             <td styleCode="Rrule">300 mg QD for 17 days</td>
                                             <td styleCode="Rrule">1.21 
     <br/>  (1.16; 1.25)
    </td>
                                             <td styleCode="Rrule">1.13 
     <br/>  (1.00; 1.28)
    </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="90%">
                                       <caption>Table 9: Effect of Canagliflozin on Systemic Exposure of Co-Administered Drugs</caption>
                                       <col width="19%" align="left" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="16%" align="center" valign="middle"/>
                                       <col width="21%" align="center" valign="middle"/>
                                       <col width="14%" align="center" valign="middle"/>
                                       <col width="14%" align="center" valign="middle"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="center" styleCode="Lrule Rrule">Co-Administered Drug</th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Co-Administered Drug
    
     <footnote ID="t8f1">Single dose unless otherwise noted</footnote>
                                             </th>
                                             <th rowspan="2" styleCode="Rrule">Dose of Canagliflozin
    
     <footnoteRef IDREF="t8f1"/>
                                             </th>
                                             <th colspan="3" styleCode="Botrule Rrule">Geometric Mean Ratio 
     <br/>  (Ratio With/Without Co-Administered Drug) 
     <br/>  No Effect = 1.0
    </th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule"/>
                                             <th styleCode="Rrule">AUC
    
     <footnote ID="K4858">AUC
                 inf for drugs given as a single dose and AUC
                 24h for drugs given as multiple doses
                </footnote>
                                                <br/>  (90% CI)
   
    </th>
                                             <th styleCode="Rrule">C
    
     <sub>max</sub>
                                                <br/>  (90% CI)
   
    </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="6">QD = once daily; BID = twice daily; INR = International Normalized Ratio</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td colspan="6" styleCode="Lrule Rrule">
                                                <content styleCode="bold">See</content>
                                                <content styleCode="bold">
                                                   <content styleCode="italics">
                                                      <linkHtml href="#S7">Drug Interactions (7)</linkHtml>
                                                   </content>
                                                </content>
                                                <content styleCode="bold">for the clinical relevance of the following:</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Digoxin</td>
                                             <td styleCode="Rrule">0.5 mg QD first day followed by 0.25 mg QD for 6 days</td>
                                             <td styleCode="Rrule">300 mg QD for 7 days</td>
                                             <td styleCode="Rrule">Digoxin</td>
                                             <td styleCode="Rrule">1.20 
     <br/>  (1.12; 1.28)
    </td>
                                             <td styleCode="Rrule">1.36 
     <br/>  (1.21; 1.53)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="6" styleCode="Lrule Rrule">
                                                <content styleCode="bold">No dose adjustments of co-administered drug required for the following:</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Acetaminophen</td>
                                             <td styleCode="Rrule">1,000 mg</td>
                                             <td styleCode="Rrule">300 mg BID for 25 days</td>
                                             <td styleCode="Rrule">Acetaminophen</td>
                                             <td styleCode="Rrule">1.06
    
     <footnote ID="K4947">AUC
                 0â12h</footnote>
                                                <br/>  (0.98; 1.14)
   
    </td>
                                             <td styleCode="Rrule">1.00 
     <br/>  (0.92; 1.09)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">Ethinyl estradiol and levonorgestrel</td>
                                             <td rowspan="2" styleCode="Rrule">0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel</td>
                                             <td rowspan="2" styleCode="Rrule">200 mg QD for 6 days</td>
                                             <td styleCode="Rrule">ethinyl estradiol</td>
                                             <td styleCode="Rrule">1.07 
     <br/>  (0.99; 1.15)
    </td>
                                             <td styleCode="Rrule">1.22 
     <br/>  (1.10; 1.35)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">Levonorgestrel</td>
                                             <td styleCode="Rrule">1.06 
     <br/>  (1.00; 1.13)
    </td>
                                             <td styleCode="Rrule">1.22 
     <br/>  (1.11; 1.35)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="3" styleCode="Lrule Rrule">Glyburide</td>
                                             <td rowspan="3" styleCode="Rrule">1.25 mg</td>
                                             <td rowspan="3" styleCode="Rrule">200 mg QD for 6 days</td>
                                             <td styleCode="Rrule">Glyburide</td>
                                             <td styleCode="Rrule">1.02 
     <br/>  (0.98; 1.07)
    </td>
                                             <td styleCode="Rrule">0.93 
     <br/>  (0.85; 1.01)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">3-cis-hydroxy-glyburide</td>
                                             <td styleCode="Rrule">1.01 
     <br/>  (0.96; 1.07)
    </td>
                                             <td styleCode="Rrule">0.99 
     <br/>  (0.91; 1.08)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">4-trans-hydroxy-glyburide</td>
                                             <td styleCode="Rrule">1.03 
     <br/>  (0.97; 1.09)
    </td>
                                             <td styleCode="Rrule">0.96 
     <br/>  (0.88; 1.04)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Hydrochlorothiazide</td>
                                             <td styleCode="Rrule">25 mg QD for 35 days</td>
                                             <td styleCode="Rrule">300 mg QD for 7 days</td>
                                             <td styleCode="Rrule">Hydrochlorothiazide</td>
                                             <td styleCode="Rrule">0.99 
     <br/>  (0.95; 1.04)
    </td>
                                             <td styleCode="Rrule">0.94 
     <br/>  (0.87; 1.01)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Metformin HCl</td>
                                             <td styleCode="Rrule">2,000 mg</td>
                                             <td styleCode="Rrule">300 mg QD for 8 days</td>
                                             <td styleCode="Rrule">Metformin HCl</td>
                                             <td styleCode="Rrule">1.20 
     <br/>  (1.08; 1.34)
    </td>
                                             <td styleCode="Rrule">1.06 
     <br/>  (0.93; 1.20)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="2" styleCode="Lrule Rrule">Simvastatin</td>
                                             <td rowspan="2" styleCode="Rrule">40 mg</td>
                                             <td rowspan="2" styleCode="Rrule">300 mg QD for 7 days</td>
                                             <td styleCode="Rrule">Simvastatin</td>
                                             <td styleCode="Rrule">1.12 
     <br/>  (0.94; 1.33)
    </td>
                                             <td styleCode="Rrule">1.09 
     <br/>  (0.91; 1.31)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">simvastatin acid</td>
                                             <td styleCode="Rrule">1.18 
     <br/>  (1.03; 1.35)
    </td>
                                             <td styleCode="Rrule">1.26 
     <br/>  (1.10; 1.45)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td rowspan="3" styleCode="Lrule Rrule">Warfarin</td>
                                             <td rowspan="3" styleCode="Rrule">30 mg</td>
                                             <td rowspan="3" styleCode="Rrule">300 mg QD for 12 days</td>
                                             <td styleCode="Rrule">(R)-warfarin</td>
                                             <td styleCode="Rrule">1.01 
     <br/>  (0.96; 1.06)
    </td>
                                             <td styleCode="Rrule">1.03 
     <br/>  (0.94; 1.13)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="center" styleCode="Rrule">(S)-warfarin</td>
                                             <td styleCode="Rrule">1.06 
     <br/>  (1.00; 1.12)
    </td>
                                             <td styleCode="Rrule">1.01 
     <br/>  (0.90; 1.13)
    </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Rrule">INR</td>
                                             <td styleCode="Rrule">1.00 
     <br/>  (0.98; 1.03)
    </td>
                                             <td styleCode="Rrule">1.05 
     <br/>  (0.99; 1.12)
    </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="2a427270-3186-bf22-e063-6294a90aaa69"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S13.1">
                     <id root="2a427270-3187-bf22-e063-6294a90aaa69"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-3188-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Carcinogenicity was evaluated in 2-year studies conducted in CD1 mice and Sprague-Dawley rats. Canagliflozin did not increase the incidence of tumors in mice dosed at 10, 30, or 100 mg/kg (less than or equal to 14 times exposure from a 300 mg clinical dose).</paragraph>
                              <paragraph>Testicular Leydig cell tumors, considered secondary to increased luteinizing hormone (LH), increased significantly in male rats at all doses tested (10, 30, and 100 mg/kg). In a 12-week clinical trial, LH did not increase in males treated with canagliflozin.</paragraph>
                              <paragraph>Renal tubular adenoma and carcinoma increased significantly in male and female rats dosed at 100 mg/kg, or approximately 12-times exposure from a 300 mg clinical dose. Also, adrenal pheochromocytoma increased significantly in males and numerically in females dosed at 100 mg/kg. Carbohydrate malabsorption associated with high doses of canagliflozin was considered a necessary proximal event in the emergence of renal and adrenal tumors in rats. Clinical trials have not demonstrated carbohydrate malabsorption in humans at canagliflozin doses of up to 2-times the recommended clinical dose of 300 mg.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3189-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Canagliflozin was not mutagenic with or without metabolic activation in the Ames assay. Canagliflozin was mutagenic in the
 
  <content styleCode="italics">in vitro</content>mouse lymphoma assay with but not without metabolic activation. Canagliflozin was not mutagenic or clastogenic in an
 
  <content styleCode="italics">in vivo</content>oral micronucleus assay in rats and an
 
  <content styleCode="italics">in vivo</content>oral Comet assay in rats.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-318a-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Canagliflozin had no effects on the ability of rats to mate and sire or maintain a litter up to the high dose of 100 mg/kg (approximately 14 times and 18 times the 300 mg clinical dose in males and females, respectively), although there were minor alterations in a number of reproductive parameters (decreased sperm velocity, increased number of abnormal sperm, slightly fewer corpora lutea, fewer implantation sites, and smaller litter sizes) at the highest dosage administered.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="2a427270-318b-bf22-e063-6294a90aaa69"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S14.1">
                     <id root="2a427270-318c-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus</title>
                     <text>
                        <paragraph>INVOKANA (canagliflozin) has been studied as monotherapy, in combination with metformin HCl, sulfonylurea, metformin HCl and sulfonylurea, metformin HCl and sitagliptin, metformin HCl and a thiazolidinedione (i.e., pioglitazone), and in combination with insulin (with or without other anti-hyperglycemic agents). The efficacy of INVOKANA was compared to a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin), both as add-on combination therapy with metformin HCl and sulfonylurea, and a sulfonylurea (glimepiride), both as add-on combination therapy with metformin HCl. INVOKANA was also evaluated in adults 55 to 80 years of age and patients with moderate renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="2a427270-318d-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Monotherapy</content>
                              </paragraph>
                              <paragraph>A total of 584 adult patients with type 2 diabetes inadequately controlled on diet and exercise participated in a 26-week double-blind, placebo-controlled trial to evaluate the efficacy and safety of INVOKANA. The mean age was 55 years, 44% of patients were male, and the mean baseline eGFR was 87 mL/min/1.73 m
 
  <sup>2</sup>. Patients taking other antihyperglycemic agents (N=281) discontinued the agent and underwent an 8-week washout followed by a 2-week, single-blind, placebo run-in period. Patients not taking oral antihyperglycemic agents (N=303) entered the 2-week, single-blind, placebo run-in period directly. After the placebo run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily for 26 weeks.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) compared to placebo. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, in significant reduction in fasting plasma glucose (FPG), in improved postprandial glucose (PPG), and in percent body weight reduction compared to placebo (see
 
  <linkHtml href="#tab10">Table 10</linkHtml>). Statistically significant (p&lt;0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -3.7 mmHg and -5.4 mmHg with INVOKANA 100 mg and 300 mg, respectively.

 </paragraph>
                              <table width="90%" ID="tab10">
                                 <caption>Table 10: Results from 26-Week Placebo-Controlled Clinical Trial with INVOKANA as Monotherapy in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K5368">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="37%" align="left" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  (N=192)
    </th>
                                       <th styleCode="Rrule">INVOKANA 
     <br/>  100 mg 
     <br/>  (N=195)
    </th>
                                       <th styleCode="Rrule">INVOKANA 
     <br/>  300 mg 
     <br/>  (N=197)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">7.97</td>
                                       <td styleCode="Rrule">8.06</td>
                                       <td styleCode="Rrule">8.01</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">0.14</td>
                                       <td styleCode="Rrule">-0.77</td>
                                       <td styleCode="Rrule">-1.03</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="t9f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.91
    
     <footnote ID="t9f3">p&lt;0.001</footnote>
                                          <br/>  (-1.09; -0.73)
   
    </td>
                                       <td styleCode="Rrule">-1.16
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-1.34; -0.99)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of Patients Achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">21</td>
                                       <td styleCode="Rrule">45
    
     <footnoteRef IDREF="t9f3"/>
                                       </td>
                                       <td styleCode="Rrule">62
    
     <footnoteRef IDREF="t9f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">166</td>
                                       <td styleCode="Rrule">172</td>
                                       <td styleCode="Rrule">173</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">-27</td>
                                       <td styleCode="Rrule">-35</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t9f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-36
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-42; -29)
   
    </td>
                                       <td styleCode="Rrule">-43
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-50; -37)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">229</td>
                                       <td styleCode="Rrule">250</td>
                                       <td styleCode="Rrule">254</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">-43</td>
                                       <td styleCode="Rrule">-59</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t9f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-48
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-59.1; -37.0)
   
    </td>
                                       <td styleCode="Rrule">-64
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-75.0; -52.9)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">87.5</td>
                                       <td styleCode="Rrule">85.9</td>
                                       <td styleCode="Rrule">86.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.6</td>
                                       <td styleCode="Rrule">-2.8</td>
                                       <td styleCode="Rrule">-3.9</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t9f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-2.2
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-2.9; -1.6)
   
    </td>
                                       <td styleCode="Rrule">-3.3
    
     <footnoteRef IDREF="t9f3"/>
                                          <br/>  (-4.0; -2.6)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-318e-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on Combination Therapy with Metformin HCl</content>
                              </paragraph>
                              <paragraph>A total of 1,284 adult patients with type 2 diabetes inadequately controlled on metformin HCl monotherapy (greater than or equal to 2,000 mg/day, or at least 1,500 mg/day if higher dose not tolerated) participated in a 26-week, double-blind, placebo- and active-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with metformin HCl. The mean age was 55 years, 47% of patients were male, and the mean baseline eGFR was 89 mL/min/1.73 m
 
  <sup>2</sup>. Patients already on the required metformin HCl dose (N=1,009) were randomized after completing a 2-week, single-blind, placebo run-in period. Patients taking less than the required metformin HCl dose or patients on metformin HCl in combination with another antihyperglycemic agent (N=275) were switched to metformin HCl monotherapy (at doses described above) for at least 8 weeks before entering the 2-week, single-blind, placebo run-in. After the placebo run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, sitagliptin 100 mg, or placebo, administered once daily as add-on therapy to metformin HCl.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) compared to placebo when added to metformin HCl. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, in significant reduction in fasting plasma glucose (FPG), in improved postprandial glucose (PPG), and in percent body weight reduction compared to placebo when added to metformin HCl (see
 
  <linkHtml href="#tab11">Table 11</linkHtml>). Statistically significant (p&lt;0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -5.4 mmHg and -6.6 mmHg with INVOKANA 100 mg and 300 mg, respectively.

 </paragraph>
                              <table width="90%" ID="tab11">
                                 <caption>Table 11: Results from 26-Week Placebo-Controlled Clinical Trial of INVOKANA in Combination with Metformin HCl in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K5713">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="38%" align="left" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="20%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Metformin HCl 
     <br/>  (N=183)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Metformin HCl 
     <br/>  (N=368)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl 
     <br/>  (N=367)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">7.96</td>
                                       <td styleCode="Rrule">7.94</td>
                                       <td styleCode="Rrule">7.95</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.17</td>
                                       <td styleCode="Rrule">-0.79</td>
                                       <td styleCode="Rrule">-0.94</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="t10f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.62
    
     <footnote ID="t10f3">p&lt;0.001</footnote>
                                          <br/>  (-0.76; -0.48)
   
    </td>
                                       <td styleCode="Rrule">-0.77
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-0.91; -0.64)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">46
    
     <footnoteRef IDREF="t10f3"/>
                                       </td>
                                       <td styleCode="Rrule">58
    
     <footnoteRef IDREF="t10f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">164</td>
                                       <td styleCode="Rrule">169</td>
                                       <td styleCode="Rrule">173</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">-27</td>
                                       <td styleCode="Rrule">-38</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t10f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-30
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-36; -24)
   
    </td>
                                       <td styleCode="Rrule">-40
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-46; -34)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">2-hour Postprandial Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">249</td>
                                       <td styleCode="Rrule">258</td>
                                       <td styleCode="Rrule">262</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-10</td>
                                       <td styleCode="Rrule">-48</td>
                                       <td styleCode="Rrule">-57</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t10f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-38
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-49; -27)
   
    </td>
                                       <td styleCode="Rrule">-47
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-58; -36)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">86.7</td>
                                       <td styleCode="Rrule">88.7</td>
                                       <td styleCode="Rrule">85.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-1.2</td>
                                       <td styleCode="Rrule">-3.7</td>
                                       <td styleCode="Rrule">-4.2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t10f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-2.5
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-3.1; -1.9)
   
    </td>
                                       <td styleCode="Rrule">-2.9
    
     <footnoteRef IDREF="t10f3"/>
                                          <br/>  (-3.5; -2.3)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-318f-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Initial Combination Therapy with Metformin HCl Extended-Release</content>
                              </paragraph>
                              <paragraph>A total of 1,186 adult patients with type 2 diabetes inadequately controlled with diet and exercise participated in a 26-week double-blind, active-controlled, parallel-group, 5-arm, multicenter trial to evaluate the efficacy and safety of initial therapy with INVOKANA in combination with metformin HCl extended-release. The median age was 56 years, 48% of patients were male, and the mean baseline eGFR was 87.6 mL/min/1.73 m
 
  <sup>2</sup>. The median duration of diabetes was 1.6 years, and 72% of patients were treatment naÃ¯ve. After completing a 2-week single-blind placebo run-in period, patients were randomly assigned for a double-blind treatment period of 26 weeks to 1 of 5 treatment groups (Table 12). The metformin HCl extended-release dose was initiated at 500 mg/day for the first week of treatment and then increased to 1,000 mg/day. Metformin HCl extended-release or matching placebo was up-titrated every 2â3 weeks during the next 8 weeks of treatment to a maximum daily dose of 1,500 to 2,000 mg/day, as tolerated; about 90% of patients reached 2,000 mg/day.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and INVOKANA 300 mg in combination with metformin HCl extended-release resulted in a statistically significant greater improvement in HbA
 
  <sub>1C</sub>compared to their respective INVOKANA doses (100 mg and 300 mg) alone or metformin HCl extended-release alone.

 </paragraph>
                              <table width="90%">
                                 <caption>Table 12: Results from 26-Week Active-Controlled Clinical Trial of INVOKANA Alone or INVOKANA as Initial Combination Therapy with Metformin HCl Extended-Release in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K6044">Intent-to-treat population</footnote>
                                 </caption>
                                 <col width="20%" align="left" valign="bottom"/>
                                 <col width="15%" align="center" valign="bottom"/>
                                 <col width="15%" align="center" valign="bottom"/>
                                 <col width="15%" align="center" valign="bottom"/>
                                 <col width="16%" align="center" valign="bottom"/>
                                 <col width="19%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Metformin HCl extended-release 
     <br/>  (N=237)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg 
     <br/>  (N=237)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg 
     <br/>  (N=238)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Metformin HCl extended-release 
     <br/>  (N=237)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl extended-release 
     <br/>  (N=237)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Baseline (mean)</td>
                                       <td styleCode="Rrule">8.81</td>
                                       <td styleCode="Rrule">8.78</td>
                                       <td styleCode="Rrule">8.77</td>
                                       <td styleCode="Rrule">8.83</td>
                                       <td styleCode="Rrule">8.90</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Change from baseline (adjusted mean)
    
     <footnote ID="K6137">There were 121 patients without week 26 efficacy data. Analyses addressing missing data gave consistent results with the results provided in this table.</footnote>
                                       </td>
                                       <td styleCode="Rrule">-1.30</td>
                                       <td styleCode="Rrule">-1.37</td>
                                       <td styleCode="Rrule">-1.42</td>
                                       <td styleCode="Rrule">-1.77</td>
                                       <td styleCode="Rrule">-1.78</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from canagliflozin 100 mg (adjusted mean) (95% CI)
    
     <footnote ID="t11f2">Least squares mean adjusted for covariates including baseline value and stratification factor</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.40
    
     <footnote ID="t11f3">Adjusted p=0.001 for superiority</footnote>
                                          <br/>  (-0.59, -0.21)
   
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from canagliflozin 300 mg (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t11f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.36
    
     <footnoteRef IDREF="t11f3"/>
                                          <br/>  (-0.56, -0.17)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from metformin HCl extended-release (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t11f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.06
    
     <footnote ID="t11f4">Adjusted p=0.001 for non-inferiority</footnote>
                                          <br/>  (-0.26, 0.13)
   
    </td>
                                       <td styleCode="Rrule">-0.11
    
     <footnoteRef IDREF="t11f4"/>
                                          <br/>  (-0.31, 0.08)
   
    </td>
                                       <td styleCode="Rrule">-0.46
    
     <footnoteRef IDREF="t11f3"/>
                                          <br/>  (-0.66, -0.27)
   
    </td>
                                       <td styleCode="Rrule">-0.48
    
     <footnoteRef IDREF="t11f3"/>
                                          <br/>  (-0.67, -0.28)
   
    </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">38</td>
                                       <td styleCode="Rrule">34</td>
                                       <td styleCode="Rrule">39</td>
                                       <td styleCode="Rrule">47
    
     <footnote ID="t11f5">Adjusted p&lt;0.05</footnote>
                                       </td>
                                       <td styleCode="Rrule">51
    
     <footnoteRef IDREF="t11f5"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3190-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">INVOKANA Compared to Glimepiride, Both as Add-on Combination With Metformin HCl</content>
                              </paragraph>
                              <paragraph>A total of 1,450 adult patients with type 2 diabetes inadequately controlled on metformin HCl monotherapy (greater than or equal to 2,000 mg/day, or at least 1,500 mg/day if higher dose not tolerated) participated in a 52-week, double-blind, active-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with metformin HCl.</paragraph>
                              <paragraph>The mean age was 56 years, 52% of patients were male, and the mean baseline eGFR was 90 mL/min/1.73 m
 
  <sup>2</sup>. Patients tolerating maximally required metformin HCl dose (N=928) were randomized after completing a 2-week, single-blind, placebo run-in period. Other patients (N=522) were switched to metformin HCl monotherapy (at doses described above) for at least 10 weeks, then completed a 2-week single-blind run-in period. After the 2-week run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or glimepiride (titration allowed throughout the 52-week trial to 6 or 8 mg), administered once daily as add-on therapy to metformin HCl.

 </paragraph>
                              <paragraph>As shown in Table 13 and Figure 1, at the end of treatment, INVOKANA 100 mg provided similar reductions in HbA
 
  <sub>1C</sub>from baseline compared to glimepiride when added to metformin HCl therapy. INVOKANA 300 mg provided a greater reduction from baseline in HbA
 
  <sub>1C</sub>compared to glimepiride, and the relative treatment difference was -0.12% (95% CI: â0.22; â0.02). As shown in Table 13, treatment with INVOKANA 100 mg and 300 mg daily provided greater improvements in percent body weight change, relative to glimepiride.

 </paragraph>
                              <table width="90%">
                                 <caption>Table 13: Results from 52âWeek Clinical Trial Comparing INVOKANA to Glimepiride in Combination with Metformin HCl in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K6301">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="36%" align="left" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="22%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Metformin HCl 
     <br/>  (N=483)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl 
     <br/>  (N=485)
    </th>
                                       <th styleCode="Rrule">Glimepiride (titrated) + Metformin HCl 
     <br/>  (N=482)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">7.78</td>
                                       <td styleCode="Rrule">7.79</td>
                                       <td styleCode="Rrule">7.83</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.82</td>
                                       <td styleCode="Rrule">-0.93</td>
                                       <td styleCode="Rrule">-0.81</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from glimepiride (adjusted mean) (95% CI)
    
     <footnote ID="t12f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule">-0.01
    
     <footnote ID="t12f3">INVOKANA + metformin HCl is considered non-inferior to glimepiride + metformin HCl because the upper limit of this confidence interval is less than the pre-specified non-inferiority margin of &lt; 0.3%.</footnote>
                                          <br/>  (-0.11; 0.09)
   
    </td>
                                       <td styleCode="Rrule">-0.12
    
     <footnoteRef IDREF="t12f3"/>
                                          <br/>  (-0.22; -0.02)
   
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">54</td>
                                       <td styleCode="Rrule">60</td>
                                       <td styleCode="Rrule">56</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">165</td>
                                       <td styleCode="Rrule">164</td>
                                       <td styleCode="Rrule">166</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-24</td>
                                       <td styleCode="Rrule">-28</td>
                                       <td styleCode="Rrule">-18</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from glimepiride (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t12f2"/>
                                       </td>
                                       <td styleCode="Rrule">-6 
     <br/>  (-10; -2)
    </td>
                                       <td styleCode="Rrule">-9 
     <br/>  (-13; -5)
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">86.8</td>
                                       <td styleCode="Rrule">86.6</td>
                                       <td styleCode="Rrule">86.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-4.2</td>
                                       <td styleCode="Rrule">-4.7</td>
                                       <td styleCode="Rrule">1.0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from glimepiride (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t12f2"/>
                                       </td>
                                       <td styleCode="Rrule">-5.2
    
     <footnote ID="t12f4">p&lt;0.001</footnote>
                                          <br/>  (-5.7; -4.7)
   
    </td>
                                       <td styleCode="Rrule">-5.7
    
     <footnoteRef IDREF="t12f4"/>
                                          <br/>  (-6.2; -5.1)
   
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" styleCode="Noautorules">
                                 <col width="100%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th>Figure 1: Mean HbA
    
     <sub>1C</sub>Change in Adults with Type 2 Diabetes Mellitus Treated with INVOKANA or Glimepiride in Combination with Metformin HCl at Each Time Point (Completers) and at Week 52 Using Last Observation Carried Forward (mITT Population)
   
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td>
                                          <renderMultiMedia referencedObject="MM2"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 1</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="invokana-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3191-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on Combination Therapy with Sulfonylurea</content>
                              </paragraph>
                              <paragraph>A total of 127 adult patients with type 2 diabetes inadequately controlled on sulfonylurea monotherapy participated in an 18-week, double-blind, placebo-controlled sub-trial to evaluate the efficacy and safety of INVOKANA in combination with sulfonylurea. The mean age was 65 years, 57% of patients were male, and the mean baseline eGFR was 69 mL/min/1.73 m
 
  <sup>2</sup>. Patients treated with sulfonylurea monotherapy on a stable protocol-specified dose (greater than or equal to 50% maximal dose) for at least 10 weeks completed a 2-week, single-blind, placebo run-in period. After the run-in period, patients with inadequate glycemic control were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily as add-on to sulfonylurea.

 </paragraph>
                              <paragraph>As shown in Table 14, at the end of treatment, INVOKANA 100 mg and 300 mg daily provided statistically significant (p&lt;0.001 for both doses) improvements in HbA
 
  <sub>1C</sub>relative to placebo when added to sulfonylurea. INVOKANA 300 mg once daily compared to placebo resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, (33% vs 5%), greater reductions in fasting plasma glucose (-36 mg/dL vs +12 mg/dL), and greater percent body weight reduction (-2.0% vs -0.2%).

 </paragraph>
                              <table width="90%">
                                 <caption>Table 14: Results from 18-Week PlaceboâControlled Clinical Trial of INVOKANA in Combination with Sulfonylurea in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K6598">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="38%" align="left" valign="bottom"/>
                                 <col width="20%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Sulfonylurea 
     <br/>  (N=45)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Sulfonylurea 
     <br/>  (N=42)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Sulfonylurea 
     <br/>  (N=40)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.49</td>
                                       <td styleCode="Rrule">8.29</td>
                                       <td styleCode="Rrule">8.28</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">0.04</td>
                                       <td styleCode="Rrule">-0.70</td>
                                       <td styleCode="Rrule">-0.79</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="K6680">Least squares mean adjusted for baseline value</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.74
    
     <footnote ID="t13f2">p&lt;0.001</footnote>
                                          <br/>  (-1.15; -0.33)
   
    </td>
                                       <td styleCode="Rrule">-0.83
    
     <footnoteRef IDREF="t13f2"/>
                                          <br/>  (-1.24; -0.41)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3192-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on Combination Therapy with Metformin HCl and Sulfonylurea</content>
                              </paragraph>
                              <paragraph>A total of 469 adult patients with type 2 diabetes inadequately controlled on the combination of metformin HCl (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (maximal or near-maximal effective dose) participated in a 26-week, double-blind, placebo-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with metformin HCl and sulfonylurea. The mean age was 57 years, 51% of patients were male, and the mean baseline eGFR was 89 mL/min/1.73 m
 
  <sup>2</sup>. Patients already on the protocol-specified doses of metformin HCl and sulfonylurea (N=372) entered a 2-week, single-blind, placebo run-in period. Other patients (N=97) were required to be on a stable protocol-specified dose of metformin HCl and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily as add-on to metformin HCl and sulfonylurea.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) compared to placebo when added to metformin HCl and sulfonylurea. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, in a significant reduction in fasting plasma glucose (FPG), and in percent body weight reduction compared to placebo when added to metformin HCl and sulfonylurea (see
 
  <linkHtml href="#tab15">Table 15</linkHtml>).

 </paragraph>
                              <table width="90%" ID="tab15">
                                 <caption>Table 15: Results from 26-Week Placebo-Controlled Clinical Trial of INVOKANA in Combination with Metformin HCl and Sulfonylurea in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K6736">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="37%" align="left" valign="bottom"/>
                                 <col width="19%" align="center" valign="bottom"/>
                                 <col width="22%" align="center" valign="bottom"/>
                                 <col width="22%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Metformin HCl and Sulfonylurea 
     <br/>  (N=156)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Metformin HCl and Sulfonylurea 
     <br/>  (N=157)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl and Sulfonylurea 
     <br/>  (N=156)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.12</td>
                                       <td styleCode="Rrule">8.13</td>
                                       <td styleCode="Rrule">8.13</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.13</td>
                                       <td styleCode="Rrule">-0.85</td>
                                       <td styleCode="Rrule">-1.06</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="t14f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.71
    
     <footnote ID="t14f3">p&lt;0.001</footnote>
                                          <br/>  (-0.90; -0.52)
   
    </td>
                                       <td styleCode="Rrule">-0.92
    
     <footnoteRef IDREF="t14f3"/>
                                          <br/>  (-1.11; -0.73)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving A
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">43
    
     <footnoteRef IDREF="t14f3"/>
                                       </td>
                                       <td styleCode="Rrule">57
    
     <footnoteRef IDREF="t14f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">170</td>
                                       <td styleCode="Rrule">173</td>
                                       <td styleCode="Rrule">168</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">-18</td>
                                       <td styleCode="Rrule">-31</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t14f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-22
    
     <footnoteRef IDREF="t14f3"/>
                                          <br/>  (-31; -13)
   
    </td>
                                       <td styleCode="Rrule">-35
    
     <footnoteRef IDREF="t14f3"/>
                                          <br/>  (-44; -25)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">90.8</td>
                                       <td styleCode="Rrule">93.5</td>
                                       <td styleCode="Rrule">93.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.7</td>
                                       <td styleCode="Rrule">-2.1</td>
                                       <td styleCode="Rrule">-2.6</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t14f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-1.4
    
     <footnoteRef IDREF="t14f3"/>
                                          <br/>  (-2.1; -0.7)
   
    </td>
                                       <td styleCode="Rrule">-2.0
    
     <footnoteRef IDREF="t14f3"/>
                                          <br/>  (-2.7; -1.3)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3193-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on Combination Therapy with Metformin HCl and Sitagliptin</content>
                              </paragraph>
                              <paragraph>A total of 217 adult patients with type 2 diabetes inadequately controlled on the combination of metformin HCl (greater than or equal to 1,500 mg/day) and sitagliptin 100 mg/day (or equivalent fixed-dose combination) participated in a 26-week, double-blind, placebo-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with metformin HCl and sitagliptin. The mean age was 57 years, 58% of patients were male, 73% of patients were White, 15% were Asian, and 12% were Black or African American. The mean baseline eGFR was 90 mL/min/1.73 m
 
  <sup>2</sup>and the mean baseline BMI was 32 kg/m
 
  <sup>2</sup>. The mean duration of diabetes was 10 years. Eligible patients entered a 2-week, single-blind, placebo run-in period and were subsequently randomized to INVOKANA 100 mg or placebo, administered once daily as add-on to metformin HCl and sitagliptin. Patients with a baseline eGFR of 70 mL/min/1.73 m
 
  <sup>2</sup>or greater who were tolerating INVOKANA 100 mg and who required additional glycemic control (fasting finger stick 100 mg/dL or greater at least twice within 2 weeks) were up-titrated to INVOKANA 300 mg. While up-titration occurred as early as Week 4, most (90%) patients randomized to INVOKANA were up-titrated to INVOKANA 300 mg by 6 to 8 weeks.

 </paragraph>
                              <paragraph>At the end of 26 weeks, INVOKANA resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001) compared to placebo when added to metformin HCl and sitagliptin.

 </paragraph>
                              <table width="90%">
                                 <caption>Table 16: Results from 26âWeek Placebo-Controlled Clinical Trial of INVOKANA in Combination with Metformin HCl and Sitagliptin in Adults with Type 2 Diabetes Mellitus</caption>
                                 <col width="50%" align="left" valign="bottom"/>
                                 <col width="25%" align="center" valign="bottom"/>
                                 <col width="25%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Metformin HCl and Sitagliptin 
     <br/>  (N=108
    
     <footnote ID="t15f1">To preserve the integrity of randomization, all randomized patients were included in the analysis. The patient who was randomized once to each arm was analyzed on INVOKANA.</footnote>)
   
    </th>
                                       <th styleCode="Rrule">INVOKANA + Metformin HCl and Sitagliptin 
     <br/>  (N=109
    
     <footnoteRef IDREF="t15f1"/>)
   
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.40</td>
                                       <td styleCode="Rrule">8.50</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.03</td>
                                       <td styleCode="Rrule">-0.83</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="K7088">Early treatment discontinuation before week 26, occurred in 11.0% and 24.1% of INVOKANA and placebo patients, respectively.</footnote>
                                          <footnote ID="K7090">Estimated using a multiple imputation method modeling a "wash-out" of the treatment effect for patients having missing data who discontinued treatment. Missing data was imputed only at week 26 and analyzed using ANCOVA.</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.81
    
     <footnote ID="t15f4">p&lt;0.001</footnote>
                                          <br/>  (-1.11; -0.51)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                          <footnote ID="K7112">Patients without week 26 efficacy data were considered as non-responders when estimating the proportion achieving HbA
               1C &lt; 7%.
              </footnote>
                                       </td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">28</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                          <footnote ID="K7131">Estimated using a multiple imputation method modeling a "wash-out" of the treatment effect for patients having missing data who discontinued treatment. A mixed model for repeated measures was used to analyze the imputed data.</footnote>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">180</td>
                                       <td styleCode="Rrule">185</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-3</td>
                                       <td styleCode="Rrule">-28</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-25
    
     <footnoteRef IDREF="t15f4"/>
                                          <br/>  (-39; -11)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3194-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">INVOKANA Compared to Sitagliptin, Both as Add-on Combination Therapy with Metformin HCl and Sulfonylurea</content>
                              </paragraph>
                              <paragraph>A total of 755 adult patients with type 2 diabetes inadequately controlled on the combination of metformin HCl (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (near-maximal or maximal effective dose) participated in a 52-week, double-blind, active-controlled trial to compare the efficacy and safety of INVOKANA 300 mg versus sitagliptin 100 mg in combination with metformin HCl and sulfonylurea. The mean age was 57 years, 56% of patients were male, and the mean baseline eGFR was 88 mL/min/1.73 m
 
  <sup>2</sup>. Patients already on protocol-specified doses of metformin HCl and sulfonylurea (N=716) entered a 2-week single-blind, placebo run-in period. Other patients (N=39) were required to be on a stable protocol-specified dose of metformin HCl and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to INVOKANA 300 mg or sitagliptin 100 mg as add-on to metformin HCl and sulfonylurea.

 </paragraph>
                              <paragraph>As shown in Table 17 and Figure 2, at the end of treatment, INVOKANA 300 mg provided greater HbA
 
  <sub>1C</sub>reduction compared to sitagliptin 100 mg when added to metformin HCl and sulfonylurea (p&lt;0.05). INVOKANA 300 mg resulted in a mean percent change in body weight from baseline of -2.5% compared to +0.3% with sitagliptin 100 mg. A mean change in systolic blood pressure from baseline of -5.06 mmHg was observed with INVOKANA 300 mg compared to +0.85 mmHg with sitagliptin 100 mg.

 </paragraph>
                              <table width="90%">
                                 <caption>Table 17: Results from 52-Week Clinical Trial Comparing INVOKANA to Sitagliptin in Combination with Metformin HCl and Sulfonylurea in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K7197">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="50%" align="left" valign="bottom"/>
                                 <col width="25%" align="center" valign="bottom"/>
                                 <col width="25%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl and Sulfonylurea 
     <br/>  (N=377)
    </th>
                                       <th styleCode="Rrule">Sitagliptin 100 mg + Metformin HCl and Sulfonylurea 
     <br/>  (N=378)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.12</td>
                                       <td styleCode="Rrule">8.13</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-1.03</td>
                                       <td styleCode="Rrule">-0.66</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from sitagliptin (adjusted mean) (95% CI)
    
     <footnote ID="t16f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule">-0.37
    
     <footnote ID="K7271">INVOKANA + metformin HCl+ sulfonylurea is considered non-inferior to sitagliptin + metformin HCl + sulfonylurea because the upper limit of this confidence interval is less than the pre-specified non-inferiority margin of &lt; 0.3%.</footnote>
                                          <br/>  (-0.50; -0.25)
   
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">48</td>
                                       <td styleCode="Rrule">35</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">170</td>
                                       <td styleCode="Rrule">164</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-30</td>
                                       <td styleCode="Rrule">-6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from sitagliptin (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t16f2"/>
                                       </td>
                                       <td styleCode="Rrule">-24 
     <br/>  (-30; -18)
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">87.6</td>
                                       <td styleCode="Rrule">89.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-2.5</td>
                                       <td styleCode="Rrule">0.3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from sitagliptin (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t16f2"/>
                                       </td>
                                       <td styleCode="Rrule">-2.8
    
     <footnote ID="K7376">p&lt;0.001</footnote>
                                          <br/>  (-3.3; -2.2)
   
    </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 2: Mean HbA
  
   <sub>1C</sub>Change in Adults with Type 2 Diabetes Mellitus Treated with INVOKANA or Sitagliptin in Combination with Metformin HCl and Sulfonylurea at Each Time Point (Completers) and at Week 52 Using Last Observation Carried Forward (mITT Population)
 
  </content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM3"/>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 2</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="invokana-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3195-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-on Combination Therapy with Metformin HCl and Pioglitazone</content>
                              </paragraph>
                              <paragraph>A total of 342 adult patients with type 2 diabetes inadequately controlled on the combination of metformin HCl (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and pioglitazone (30 or 45 mg/day) participated in a 26-week, double-blind, placebo-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with metformin HCl and pioglitazone. The mean age was 57 years, 63% of patients were male, and the mean baseline eGFR was 86 mL/min/1.73 m
 
  <sup>2</sup>. Patients already on protocol-specified doses of metformin HCl and pioglitazone (N=163) entered a 2-week, single-blind, placebo run-in period.

 </paragraph>
                              <paragraph>Other patients (N=181) were required to be on stable protocol-specified doses of metformin HCl and pioglitazone for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily as add-on to metformin HCl and pioglitazone.</paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) compared to placebo when added to metformin HCl and pioglitazone. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, in significant reduction in fasting plasma glucose (FPG) and in percent body weight reduction compared to placebo when added to metformin HCl and pioglitazone (see
 
  <linkHtml href="#tab18">Table 18</linkHtml>). Statistically significant (p&lt;0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -4.1 mmHg and -3.5 mmHg with INVOKANA 100 mg and 300 mg, respectively.

 </paragraph>
                              <table width="90%" ID="tab18">
                                 <caption>Table 18: Results from 26-Week Placebo-Controlled Clinical Trial of INVOKANA in Combination with Metformin HCl and Pioglitazone in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K7438">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="37%" align="left" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <col width="21%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Metformin HCl and Pioglitazone 
     <br/>  (N=115)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Metformin HCl and Pioglitazone 
     <br/>  (N=113)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Metformin HCl and Pioglitazone 
     <br/>  (N=114)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.00</td>
                                       <td styleCode="Rrule">7.99</td>
                                       <td styleCode="Rrule">7.84</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.26</td>
                                       <td styleCode="Rrule">-0.89</td>
                                       <td styleCode="Rrule">-1.03</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="t17f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.62
    
     <footnote ID="t17f3">p&lt;0.001</footnote>
                                          <br/>  (-0.81; -0.44)
   
    </td>
                                       <td styleCode="Rrule">-0.76
    
     <footnoteRef IDREF="t17f3"/>
                                          <br/>  (-0.95; -0.58)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">47
    
     <footnoteRef IDREF="t17f3"/>
                                       </td>
                                       <td styleCode="Rrule">64
    
     <footnoteRef IDREF="t17f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">164</td>
                                       <td styleCode="Rrule">169</td>
                                       <td styleCode="Rrule">164</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">-27</td>
                                       <td styleCode="Rrule">-33</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t17f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-29
    
     <footnoteRef IDREF="t17f3"/>
                                          <br/>  (-37; -22)
   
    </td>
                                       <td styleCode="Rrule">-36
    
     <footnoteRef IDREF="t17f3"/>
                                          <br/>  (-43; -28)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">94.0</td>
                                       <td styleCode="Rrule">94.2</td>
                                       <td styleCode="Rrule">94.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">-0.1</td>
                                       <td styleCode="Rrule">-2.8</td>
                                       <td styleCode="Rrule">-3.8</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnoteRef IDREF="t17f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-2.7
    
     <footnoteRef IDREF="t17f3"/>
                                          <br/>  (-3.6; -1.8)
   
    </td>
                                       <td styleCode="Rrule">-3.7
    
     <footnoteRef IDREF="t17f3"/>
                                          <br/>  (-4.6; -2.8)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3196-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Add-On Combination Therapy with Insulin (With or Without Other Antihyperglycemic Agents)</content>
                              </paragraph>
                              <paragraph>A total of 1,718 adult patients with type 2 diabetes inadequately controlled on insulin greater than or equal to 30 units/day or insulin in combination with other antihyperglycemic agents participated in an 18-week, double-blind, placebo-controlled subtrial of a cardiovascular trial to evaluate the efficacy and safety of INVOKANA in combination with insulin. The mean age was 63 years, 66% of patients were male, and the mean baseline eGFR was 75 mL/min/1.73 m
 
  <sup>2</sup>. Patients on basal, bolus, or basal/bolus insulin for at least 10 weeks entered a 2-week, single-blind, placebo run-in period. Approximately 70% of patients were on a background basal/bolus insulin regimen. After the run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily as add-on to insulin. The mean daily insulin dose at baseline was 83 units, which was similar across treatment groups.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) compared to placebo when added to insulin. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA
 
  <sub>1C</sub>less than 7%, in significant reductions in fasting plasma glucose (FPG), and in percent body weight reductions compared to placebo (see
 
  <linkHtml href="#tab19">Table 19</linkHtml>). Statistically significant (p&lt;0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -2.6 mmHg and -4.4 mmHg with INVOKANA 100 mg and 300 mg, respectively.

 </paragraph>
                              <table width="90%" ID="tab19">
                                 <caption>Table 19: Results from 18-Week Placebo-Controlled Clinical Trial of INVOKANA in Combination with Insulin â¥ 30 Units/Day (With or Without Other Oral Antihyperglycemic Agents) in Adults with Type 2 Diabetes Mellitus
  
   <footnote ID="K7718">Intent-to-treat population using last observation in the trial prior to glycemic rescue therapy</footnote>
                                 </caption>
                                 <col width="36%" align="left" valign="bottom"/>
                                 <col width="20%" align="center" valign="bottom"/>
                                 <col width="20%" align="center" valign="bottom"/>
                                 <col width="24%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                       <th styleCode="Rrule">Placebo + Insulin 
     <br/>  (N=565)
    </th>
                                       <th styleCode="Rrule">INVOKANA 100 mg + Insulin 
     <br/>  (N=566)
    </th>
                                       <th styleCode="Rrule">INVOKANA 300 mg + Insulin 
     <br/>  (N=587)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                       <td styleCode="Rrule">8.20</td>
                                       <td styleCode="Rrule">8.33</td>
                                       <td styleCode="Rrule">8.27</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">0.01</td>
                                       <td styleCode="Rrule">-0.63</td>
                                       <td styleCode="Rrule">-0.72</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (95% CI)
    
     <footnote ID="t18f2">Least squares mean adjusted for baseline value and stratification factors</footnote>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.65
    
     <footnote ID="t18f3">p&lt;0.001</footnote>
                                          <br/>  (-0.73; -0.56)
   
    </td>
                                       <td styleCode="Rrule">-0.73
    
     <footnoteRef IDREF="t18f3"/>
                                          <br/>  (-0.82; -0.65)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Percent of patients achieving HbA
     
      <sub>1C</sub>&lt; 7%
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">20
    
     <footnoteRef IDREF="t18f3"/>
                                       </td>
                                       <td styleCode="Rrule">25
    
     <footnoteRef IDREF="t18f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline</td>
                                       <td styleCode="Rrule">169</td>
                                       <td styleCode="Rrule">170</td>
                                       <td styleCode="Rrule">168</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">-19</td>
                                       <td styleCode="Rrule">-25</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (97.5% CI)
    
     <footnoteRef IDREF="t18f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-23
    
     <footnoteRef IDREF="t18f3"/>
                                          <br/>  (-29; -16)
   
    </td>
                                       <td styleCode="Rrule">-29
    
     <footnoteRef IDREF="t18f3"/>
                                          <br/>  (-35; -23)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Body Weight</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Baseline (mean) in kg</td>
                                       <td styleCode="Rrule">97.7</td>
                                       <td styleCode="Rrule">96.9</td>
                                       <td styleCode="Rrule">96.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â % change from baseline (adjusted mean)</td>
                                       <td styleCode="Rrule">0.1</td>
                                       <td styleCode="Rrule">-1.8</td>
                                       <td styleCode="Rrule">-2.3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Difference from placebo (adjusted mean) (97.5% CI)
    
     <footnoteRef IDREF="t18f2"/>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-1.9
    
     <footnoteRef IDREF="t18f3"/>
                                          <br/>  (-2.2; -1.6)
   
    </td>
                                       <td styleCode="Rrule">-2.4
    
     <footnoteRef IDREF="t18f3"/>
                                          <br/>  (-2.7; -2.1)
   
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3197-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Trial in Patients Ages 55 to 80</content>
                              </paragraph>
                              <paragraph>A total of 714 type 2 diabetes patients ages 55 to 80 years and inadequately controlled on current diabetes therapy (either diet and exercise alone or in combination with oral or parenteral agents) participated in a 26-week, double-blind, placebo-controlled trial to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment. The mean age was 64 years, 55% of patients were male, and the mean baseline eGFR was 77 mL/min/1.73 m
 
  <sup>2</sup>. Patients were randomized in a 1:1:1 ratio to the addition of INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily. At the end of treatment, INVOKANA provided statistically significant improvements from baseline relative to placebo in HbA
 
  <sub>1C</sub>(p&lt;0.001 for both doses) of -0.57% (95% CI: -0.71%; -0.44%) for INVOKANA 100 mg and -0.70% (95% CI: -0.84%; -0.57%) for INVOKANA 300 mg
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a427270-3198-bf22-e063-6294a90aaa69"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Glycemic Control in Patients with Moderate Renal Impairment</content>
                              </paragraph>
                              <paragraph>A total of 269 adult patients with type 2 diabetes and a baseline eGFR of 30 mL/min/1.73 m
 
  <sup>2</sup>to less than 50 mL/min/1.73 m
 
  <sup>2</sup>inadequately controlled on current diabetes therapy participated in a 26-week, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment (diet or antihyperglycemic agent therapy, with 95% of patients on insulin and/or sulfonylurea). The mean age was 68 years, 61% of patients were male, and the mean baseline eGFR was 39 mL/min/1.73 m
 
  <sup>2</sup>. Patients were randomized in a 1:1:1 ratio to the addition of INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily.

 </paragraph>
                              <paragraph>At the end of treatment, INVOKANA 100 mg and INVOKANA 300 mg daily provided greater reductions in HbA
 
  <sub>1C</sub>relative to placebo (-0.30% [95% CI: -0.53%; -0.07%] and -0.40%, [95% CI: -0.64%; -0.17%], respectively)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>,
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, and
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="2a427270-3199-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Glycemic Control Trial in Pediatric Patients Aged 10 Years and Older with Type 2 Diabetes Mellitus</title>
                     <text>
                        <paragraph>In a double-blind, placebo-controlled, parallel-group pediatric trial (NCT03170518), 171 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes mellitus (HbA
 
  <sub>1C</sub>â¥6.5% and â¤11.0%) were randomized to INVOKANA (84 patients) or placebo (87 patients) as add-on to diet and exercise, metformin HCl (â¥1,000 mg per day or maximally tolerated dosage), insulin, or a combination of metformin HCl and insulin, for a total of 52-weeks. At Week 13, patients in the INVOKANA arm whose HbA
 
  <sub>1C</sub>was â¥7.0% and eGFR â¥60 mL/min/1.73 m
 
  <sup>2</sup>were re-randomized to either continue on INVOKANA 100 mg orally once daily (n=16) or to up-titrate to INVOKANA 300 mg orally once daily (n=17).

 </paragraph>
                        <paragraph>At baseline, background therapies included diet and exercise only (14%), insulin monotherapy (11%), metformin HCl and insulin (29%), and metformin HCl monotherapy (46%). The mean HbA
 
  <sub>1C</sub>at baseline was 8.0% and the mean duration of type 2 diabetes mellitus was 2 years. The mean eGFR at baseline was 157.3 mL/min/1.73 m
 
  <sup>2</sup>, and approximately 16% (24/151) of the trial population with measurements had microalbuminuria or macroalbuminuria. Patients with an eGFR less than 60 mL/min/1.73 m
 
  <sup>2</sup>were not enrolled in the trial; no patients in the trial reached an eGFR &lt; 60 mL/min/1.73 m
 
  <sup>2</sup>. The mean age was 14.3 years, 47% were under 15 years of age, and 68% were female. Approximately 42% were Asian, 42% were White, 11% were Black or African American, 5% were American Indian/Alaska Native, and 36% were of Hispanic or Latino ethnicity. The mean BMI was 30.8 kg/m
 
  <sup>2</sup>(range 18â57 kg/m
 
  <sup>2</sup>) and the mean BMI Z-score was 1.84.

 </paragraph>
                        <paragraph>At Week 26, treatment with canagliflozin provided statistically significant improvement in HbA
 
  <sub>1C</sub>from baseline, compared with placebo (see
 
  <linkHtml href="#tab20">Table 20</linkHtml>).

 </paragraph>
                        <table width="90%" ID="tab20">
                           <caption>Table 20: Results at Week 26 in a Placebo-Controlled Trial of INVOKANA in Combination with Metformin HCl and/or Insulin or as Monotherapy in Pediatric Patients Aged 10 Years and Older with Type 2 Diabetes Mellitus
  
   <footnote ID="K8310">Modified intent-to-treat set (All randomized and treated patients with baseline HbA
           1C measurement).
          </footnote>
                           </caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                                 <th styleCode="Rrule">Placebo 
     <br/>  (N=87)
    </th>
                                 <th styleCode="Rrule">INVOKANA 
     <br/>  (N=84)
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">HbA
     
      <sub>1C</sub>(%)
    
     </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                 <td styleCode="Rrule">8.3</td>
                                 <td styleCode="Rrule">7.8</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Change from baseline
    
     <footnote ID="t20ft1">Multiple imputation using retrieved dropout approach with 1000 iterations for missing data (canagliflozin N=7 (8.3%), placebo N=7 (8.1%) for HbA
             1C and canagliflozin N=9 (10.7%), placebo N=7 (8.1%) for FPG).
            </footnote>
                                    <footnote ID="t20ft2">Least-Square Mean from Analysis of Covariance (ANCOVA) adjusted for baseline value, baseline age stratum (&lt; 15 years vs 15 to &lt; 18 years) and baseline antihyperglycemic agent (AHA) background (i.e, diet and exercise only, metformin monotherapy, insulin monotherapy, or combination of insulin and metformin).</footnote>
                                 </td>
                                 <td styleCode="Rrule">0.34</td>
                                 <td styleCode="Rrule">-0.38</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Difference from placebo 95% CI
    
     <footnoteRef IDREF="t20ft1"/>
                                    <footnoteRef IDREF="t20ft2"/>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-0.73 (-1.26, -0.19)
    
     <footnote ID="K8399">P-value=0.008 (two-sided)</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">FPG (mg/dL)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Baseline (mean)</td>
                                 <td styleCode="Rrule">156.5</td>
                                 <td styleCode="Rrule">154.8</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Change from baseline
    
     <footnoteRef IDREF="t20ft1"/>
                                    <footnoteRef IDREF="t20ft2"/>
                                 </td>
                                 <td styleCode="Rrule">17.29</td>
                                 <td styleCode="Rrule">-8.22</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Difference from placebo 95% CI
    
     <footnoteRef IDREF="t20ft1"/>
                                    <footnoteRef IDREF="t20ft2"/>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-25.51 (-49.55, -1.47)
    
     <footnote ID="K8449">Not evaluated for statistical significance, not part of sequential testing procedure.</footnote>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="2a427270-319a-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Cardiovascular Outcomes in Adults with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease</title>
                     <text>
                        <paragraph>The CANVAS and CANVAS-R trials were multicenter, multi-national, randomized, double-blind parallel group, with similar inclusion and exclusion criteria. Patients eligible for enrollment in both CANVAS and CANVAS-R trials were: 30 years of age or older and had established, stable, cardiovascular, cerebrovascular, peripheral artery disease (66% of the enrolled population) or were 50 years of age or older and had two or more other specified risk factors for cardiovascular disease (34% of the enrolled population).</paragraph>
                        <paragraph>The integrated analysis of the CANVAS and CANVAS-R trials compared the risk of Major Adverse Cardiovascular Event (MACE) between canagliflozin and placebo when these were added to and used concomitantly with standard of care treatments for diabetes and atherosclerotic cardiovascular disease. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.</paragraph>
                        <paragraph>In CANVAS, patients were randomly assigned 1:1:1 to canagliflozin 100 mg, canagliflozin 300 mg, or matching placebo. In CANVAS-R, patients were randomly assigned 1:1 to canagliflozin 100 mg or matching placebo, and titration to 300 mg was permitted at the investigator's discretion (based on tolerability and glycemic needs) after Week 13. Concomitant antidiabetic and atherosclerotic therapies could be adjusted, at the discretion of investigators, to ensure participants were treated according to the standard care for these diseases.</paragraph>
                        <paragraph>A total of 10,134 adult patients were treated (4,327 in CANVAS and 5,807 in CANVAS-R; total of 4,344 randomly assigned to placebo and 5,790 to canagliflozin) for a mean exposure duration of 149 weeks (223 weeks [4.3 years] in CANVAS and 94 weeks [1.8 years] in CANVAS-R)
 
  <content styleCode="italics">.</content>Approximately 78% of the trial population was White, 13% was Asian, and 3% was Black or African American. The mean age was 63 years and approximately 64% were male.

 </paragraph>
                        <paragraph>The mean HbA
 
  <sub>1C</sub>at baseline was 8.2% and mean duration of diabetes was 13.5 years with 70% of patients having had diabetes for 10 years or more. Approximately 31%, 21% and 17% reported a past history of neuropathy, retinopathy and nephropathy, respectively, and the mean eGFR 76 mL/min/1.73 m
 
  <sup>2</sup>. At baseline, patients were treated with one (19%) or more (80%) antidiabetic medications including metformin HCl (77%), insulin (50%), and sulfonylurea (43%).

 </paragraph>
                        <paragraph>At baseline, the mean systolic blood pressure was 137 mmHg, the mean diastolic blood pressure was 78 mmHg, the mean LDL was 89 mg/dL, the mean HDL was 46 mg/dL, and the mean urinary albumin to creatinine ratio (UACR) was 115 mg/g. At baseline, approximately 80% of patients were treated with renin angiotensin system inhibitors, 53% with beta-blockers, 13% with loop diuretics, 36% with non-loop diuretics, 75% with statins, and 74% with antiplatelet agents (mostly aspirin). During the trial, investigators could modify anti-diabetic and cardiovascular therapies to achieve local standard of care treatment targets with respect to blood glucose, lipid, and blood pressure. More patients receiving canagliflozin compared to placebo initiated anti-thrombotics (5.2% vs 4.2%) and statins (5.8% vs 4.8%) during the trial.</paragraph>
                        <paragraph>For the primary analysis, a stratified Cox proportional hazards model was used to test for non-inferiority against a pre-specified risk margin of 1.3 for the hazard ratio of MACE.</paragraph>
                        <paragraph>In the integrated analysis of CANVAS and CANVAS-R trials, canagliflozin reduced the risk of first occurrence of MACE. The estimated hazard ratio (95% CI) for time to first MACE was 0.86 (0.75, 0.97). Refer to Table 21. Vital status was obtained for 99.6% of patients across the trials. The Kaplan-Meier curve depicting time to first occurrence of MACE is shown in Figure 3.</paragraph>
                        <table width="90%" ID="tab21">
                           <caption>Table 21: Treatment Effect for the Primary Composite Endpoint, MACE, and its Components in the Integrated Analysis of CANVAS and CANVAS-R Trials in Adults with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
  
   <footnote ID="K8087">Intent-To-Treat Analysis Set</footnote>
                           </caption>
                           <col width="44%" align="left" valign="middle"/>
                           <col width="16%" align="left" valign="middle"/>
                           <col width="18%" align="left" valign="middle"/>
                           <col width="22%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Placebo 
     <br/>  N=4,347(%)
    </th>
                                 <th styleCode="Rrule">Canagliflozin 
     <br/>  N=5,795 (%)
    </th>
                                 <th styleCode="Rrule">Hazard ratio 
     <br/>  (95% C.I.)
    
     <footnote ID="K8124">Stratified Cox-proportional hazards model with treatment as a factor and stratified by the trial and by prior CV disease</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke 
     <br/>  (time to first occurrence)
    
     <footnote ID="K8134">P-value for superiority (2-sided) = 0.0158</footnote>
                                    <sup>,</sup>
                                    <footnote ID="t19f4">Number and percentage of first events</footnote>
                                    <sup>,</sup>
                                    <footnote ID="t19f5">Due to pooling of unequal randomization ratios, Cochran-Mantel-Haenszel weights were applied to calculate percentages</footnote>
                                 </td>
                                 <td styleCode="Rrule">426 (10.4)</td>
                                 <td styleCode="Rrule">585 (9.2)</td>
                                 <td styleCode="Rrule">0.86 (0.75, 0.97)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Non-fatal myocardial infarction
    
     <footnoteRef IDREF="t19f4"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t19f5"/>
                                 </td>
                                 <td styleCode="Rrule">159 (3.9)</td>
                                 <td styleCode="Rrule">215 (3.4)</td>
                                 <td styleCode="Rrule">0.85 (0.69, 1.05)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Non-fatal Stroke
    
     <footnoteRef IDREF="t19f4"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t19f5"/>
                                 </td>
                                 <td styleCode="Rrule">116 (2.8)</td>
                                 <td styleCode="Rrule">158 (2.5)</td>
                                 <td styleCode="Rrule">0.90 (0.71, 1.15)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Cardiovascular Death
    
     <footnoteRef IDREF="t19f4"/>
                                    <sup>,</sup>
                                    <footnoteRef IDREF="t19f5"/>
                                 </td>
                                 <td styleCode="Rrule">185 (4.6)</td>
                                 <td styleCode="Rrule">268 (4.1)</td>
                                 <td styleCode="Rrule">0.87 (0.72, 1.06)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Time to First Occurrence of MACE in Adults with Type 2 Diabetes Mellitus</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Figure 3</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="invokana-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="2a427270-319b-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Renal and Cardiovascular Outcomes in Adults with Diabetic Nephropathy and Albuminuria</title>
                     <text>
                        <paragraph>The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial (CREDENCE) was a multinational, randomized, double-blind, placebo-controlled trial comparing canagliflozin with placebo in adult patients with type 2 diabetes mellitus, an eGFR â¥ 30 to &lt; 90 mL/min/1.73 m
 
  <sup>2</sup>and albuminuria (urine albumin/creatinine &gt; 300 to â¤ 5,000 mg/g) who were receiving standard of care including a maximum-tolerated, labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

 </paragraph>
                        <paragraph>The primary objective of CREDENCE was to assess the efficacy of canagliflozin relative to placebo in reducing the composite endpoint of end stage kidney disease (ESKD), doubling of serum creatinine, and renal or CV death.</paragraph>
                        <paragraph>Patients were randomized to receive canagliflozin 100 mg (N=2,202) or placebo (N=2,199) and treatment was continued until the initiation of dialysis or renal transplantation.</paragraph>
                        <paragraph>The median follow-up duration for the 4,401 randomized subjects was 137 weeks. Vital status was obtained for 99.9% of subjects.</paragraph>
                        <paragraph>The population was 67% White, 20% Asian, and 5% Black or African American; 32% were of Hispanic or Latino ethnicity. The mean age was 63 years and 66% were male.</paragraph>
                        <paragraph>At randomization, the mean HbA
 
  <sub>1C</sub>was 8.3%, the median urine albumin/creatinine was 927 mg/g, the mean eGFR was 56.2 mL/min/1.73 m
 
  <sup>2</sup>, 50% had prior CV disease, and 15% reported a history of heart failure. The most frequent antihyperglycemic agents (AHA) medications used at baseline were insulin (66%), biguanides (58%), and sulfonylureas (29%). Nearly all subjects (99.9%) were on ACEi or ARB at randomization, approximately 60% were taking an anti-thrombotic agent (including aspirin), and 69% were on a statin.

 </paragraph>
                        <paragraph>The primary composite endpoint in the CREDENCE trial was the time to first occurrence of ESKD (defined as an eGFR &lt; 15 mL/min/1.73 m
 
  <sup>2</sup>, initiation of chronic dialysis or renal transplant), doubling of serum creatinine, and renal or CV death. Canagliflozin 100 mg significantly reduced the risk of the primary composite endpoint based on a time-to-event analysis [HR: 0.70; 95% CI: 0.59, 0.82; p&lt;0.0001] (see
 
  <linkHtml href="#fig4">Figure 4</linkHtml>). The treatment effect reflected a reduction in progression to ESKD, doubling of serum creatinine and cardiovascular death as shown in Table 22 and Figure 4. There were few renal deaths during the trial. Canagliflozin 100 mg also significantly reduced the risk of hospitalization for heart failure [HR: 0.61; 95% CI: 0.47 to 0.80; p&lt;0.001].

 </paragraph>
                        <table width="100%">
                           <caption>Table 22: Analysis of Primary Endpoint (including the Individual Components) and Secondary Endpoints from the CREDENCE Trial in Adults with Diabetic Nephropathy and Albuminuria</caption>
                           <col width="35%" align="left" valign="top"/>
                           <col width="13%" align="left" valign="top"/>
                           <col width="13%" align="left" valign="top"/>
                           <col width="13%" align="left" valign="top"/>
                           <col width="13%" align="left" valign="top"/>
                           <col width="13%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Botrule"/>
                                 <th colspan="2" align="center" styleCode="Rrule Botrule">Placebo</th>
                                 <th colspan="2" align="center" styleCode="Rrule Botrule">canagliflozin</th>
                                 <th styleCode="Rrule Botrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule">Endpoint</th>
                                 <th styleCode="Rrule">N=2,199 (%)</th>
                                 <th styleCode="Rrule">Event Rate
    
     <footnote ID="fn20a">Event rate per 100 patient-years.</footnote>
                                 </th>
                                 <th styleCode="Rrule">N=2,202 (%)</th>
                                 <th styleCode="Rrule">Event Rate
    
     <footnoteRef IDREF="fn20a"/>
                                 </th>
                                 <th styleCode="Rrule">HR
    
     <footnote ID="fn20b">Hazard ratio (canagliflozin compared to placebo), 95% CI and p-value are estimated using a stratified Cox proportional hazards model including treatment as the explanatory variable and stratified by screening eGFR (â¥ 30 to &lt; 45, â¥ 45 to &lt; 60, â¥ 60 to &lt; 90 mL/min/1.73 m
             2).  HR is not presented for renal death due to the small number of events in each group.
            </footnote>
                                    <br/>  (95% CI)
   
    </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">Intent-To-Treat Analysis Set (time to first occurrence)</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">The individual components do not represent a breakdown of the composite outcomes, but rather the total number of subjects experiencing an event during the course of the trial.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Primary Composite Endpoint (ESKD, doubling of serum creatinine, renal death, or CV death)</td>
                                 <td styleCode="Rrule">340 (15.5)</td>
                                 <td styleCode="Rrule">6.1</td>
                                 <td styleCode="Rrule">245 (11.1)</td>
                                 <td styleCode="Rrule">4.3</td>
                                 <td styleCode="Rrule">0.70 
     <br/>  (0.59, 0.82)
    
     <footnote ID="fn20c">P-value &lt;0.0001</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â ESKD</td>
                                 <td styleCode="Rrule">165 (7.5)</td>
                                 <td styleCode="Rrule">2.9</td>
                                 <td styleCode="Rrule">116 (5.3)</td>
                                 <td styleCode="Rrule">2.0</td>
                                 <td styleCode="Rrule">0.68 
     <br/>  (0.54, 0.86)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Doubling of serum creatinine</td>
                                 <td styleCode="Rrule">188 (8.5)</td>
                                 <td styleCode="Rrule">3.4</td>
                                 <td styleCode="Rrule">118 (5.4)</td>
                                 <td styleCode="Rrule">2.1</td>
                                 <td styleCode="Rrule">0.60 
     <br/>  (0.48, 0.76)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Renal death</td>
                                 <td styleCode="Rrule">5 (0.2)</td>
                                 <td styleCode="Rrule">0.1</td>
                                 <td styleCode="Rrule">2 (0.1)</td>
                                 <td styleCode="Rrule">0.0</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â CV death</td>
                                 <td styleCode="Rrule">140 (6.4)</td>
                                 <td styleCode="Rrule">2.4</td>
                                 <td styleCode="Rrule">110 (5.0)</td>
                                 <td styleCode="Rrule">1.9</td>
                                 <td styleCode="Rrule">0.78 
     <br/>  (0.61, 1.00)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">CV death or hospitalization for heart failure</td>
                                 <td styleCode="Rrule">253 (11.5)</td>
                                 <td styleCode="Rrule">4.5</td>
                                 <td styleCode="Rrule">179 (8.1)</td>
                                 <td styleCode="Rrule">3.1</td>
                                 <td styleCode="Rrule">0.69 
     <br/>  (0.57, 0.83)
    
     <footnote ID="fn20d">P-value &lt;0.001</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">CV death, non-fatal myocardial infarction or non-fatal stroke</td>
                                 <td styleCode="Rrule">269 (12.2)</td>
                                 <td styleCode="Rrule">4.9</td>
                                 <td styleCode="Rrule">217 (9.9)</td>
                                 <td styleCode="Rrule">3.9</td>
                                 <td styleCode="Rrule">0.80 
     <br/>  (0.67, 0.95)
    
     <footnote ID="K8520">P-value &lt;0.02</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Non-fatal myocardial infarction</td>
                                 <td styleCode="Rrule">87 (4.0)</td>
                                 <td styleCode="Rrule">1.6</td>
                                 <td styleCode="Rrule">71 (3.2)</td>
                                 <td styleCode="Rrule">1.3</td>
                                 <td styleCode="Rrule">0.81 
     <br/>  (0.59, 1.10)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Non-fatal stroke</td>
                                 <td styleCode="Rrule">66 (3.0)</td>
                                 <td styleCode="Rrule">1.2</td>
                                 <td styleCode="Rrule">53 (2.4)</td>
                                 <td styleCode="Rrule">0.9</td>
                                 <td styleCode="Rrule">0.80 
     <br/>  (0.56, 1.15)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hospitalization for heart failure</td>
                                 <td styleCode="Rrule">141 (6.4)</td>
                                 <td styleCode="Rrule">2.5</td>
                                 <td styleCode="Rrule">89 (4.0)</td>
                                 <td styleCode="Rrule">1.6</td>
                                 <td styleCode="Rrule">0.61 
     <br/>  (0.47, 0.80)
    
     <footnoteRef IDREF="fn20d"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">ESKD, doubling of serum creatinine or renal death</td>
                                 <td styleCode="Rrule">224 (10.2)</td>
                                 <td styleCode="Rrule">4.0</td>
                                 <td styleCode="Rrule">153 (6.9)</td>
                                 <td styleCode="Rrule">2.7</td>
                                 <td styleCode="Rrule">0.66 
     <br/>  (0.53, 0.81)
    
     <footnoteRef IDREF="fn20c"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The Kaplan-Meier curve (Figure 4) shows time to first occurrence of the primary composite endpoint of ESKD, doubling of serum creatinine, renal death, or CV death. The curves begin to separate by Week 52 and continue to diverge thereafter.</paragraph>
                        <paragraph ID="fig4">
                           <content styleCode="bold">Figure 4: CREDENCE: Time to First Occurrence of the Primary Composite Endpoint</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM5"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Figure 4</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="invokana-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="2a427270-319c-bf22-e063-6294a90aaa69"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>INVOKANA
 
  <sup>Â®</sup>(canagliflozin) tablets are available in the strengths and packages listed below:

 </paragraph>
                  <paragraph>100 mg tablets are yellow, capsule-shaped, film-coated tablets with "CFZ" on one side and "100" on the other side.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="23%" align="left" valign="top"/>
                     <col width="77%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Â Â NDC 50458-140-30</td>
                           <td>Bottle of 30</td>
                        </tr>
                        <tr>
                           <td>Â Â NDC 50458-140-90</td>
                           <td>Bottle of 90</td>
                        </tr>
                        <tr>
                           <td>Â Â NDC 50458-140-50</td>
                           <td>Bottle of 500</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>300 mg tablets are white, capsule-shaped, film-coated tablets with "CFZ" on one side and "300" on the other side.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="23%" align="left" valign="top"/>
                     <col width="77%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Â Â NDC 50458-141-30</td>
                           <td>Bottle of 30</td>
                        </tr>
                        <tr>
                           <td>Â Â NDC 50458-141-90</td>
                           <td>Bottle of 90</td>
                        </tr>
                        <tr>
                           <td>Â Â NDC 50458-141-50</td>
                           <td>Bottle of 500</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <section>
                     <id root="2a427270-319d-bf22-e063-6294a90aaa69"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                           <br/>  Keep out of reach of children.

 </paragraph>
                        <paragraph>Store at 20 Â°C to 25 Â°C (68 Â°F to 77 Â°F); excursions permitted between 15 Â°C to 30 Â°C (59 Â°F to 86 Â°F)
 
  <content styleCode="italics">[see USP Controlled Room Temperature]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="2a427270-319e-bf22-e063-6294a90aaa69"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <section>
                     <id root="2a427270-319f-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis</content>
                        </paragraph>
                        <paragraph>Inform patients that INVOKANA can cause potentially fatal ketoacidosis and that type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are risk factors.</paragraph>
                        <paragraph>Educate all patients on precipitating factors (such as insulin dose reduction or missed doses, infection, reduced caloric intake, ketogenic diet, surgery, dehydration, and alcohol abuse) and symptoms of ketoacidosis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing). Inform patients that blood glucose may be normal even in the presence of ketoacidosis.</paragraph>
                        <paragraph>Advise patients that they may be asked to monitor ketones. If symptoms of ketoacidosis occur, instruct patients to discontinue INVOKANA and seek medical attention immediately
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a0-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lower Limb Amputation</content>
                        </paragraph>
                        <paragraph>Inform patients that INVOKANA is associated with an increased risk of amputations. Counsel patients about the importance of routine preventative foot care. Instruct patients to monitor for new pain or tenderness, sores or ulcers, or infections involving the leg or foot and to seek medical advice immediately if such signs or symptoms develop
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a1-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Volume Depletion</content>
                        </paragraph>
                        <paragraph>Inform patients that symptomatic hypotension may occur with INVOKANA and advise them to contact their doctor if they experience such symptoms
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>. Inform patients that dehydration may increase the risk for hypotension, and to have adequate fluid intake.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a2-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</content>
                        </paragraph>
                        <paragraph>Inform patients that hypoglycemia has been reported when INVOKANA is used with insulin or insulin secretagogues. Educate patients or caregivers on the signs and symptoms of hypoglycemia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a3-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Urinary Tract Infections</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential for urinary tract infections, which may be serious. Provide them with information on the symptoms of urinary tract infections. Advise them to seek medical advice if such symptoms occur
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a4-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Necrotizing Fasciitis of the Perineum (Fournier's Gangrene)</content>
                        </paragraph>
                        <paragraph>Inform patients that necrotizing infections of the perineum (Fournier's gangrene) have occurred with INVOKANA. Counsel patients to promptly seek medical attention if they develop pain or tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, along with a fever above 100.4Â°F or malaise
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a5-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Genital Mycotic Infections in Females (e.g., Vulvovaginitis)</content>
                        </paragraph>
                        <paragraph>Inform female patients that vaginal yeast infection may occur and provide them with information on the signs and symptoms of vaginal yeast infection. Advise them of treatment options and when to seek medical advice
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a6-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Genital Mycotic Infections in Males (e.g., Balanitis or Balanoposthitis)</content>
                        </paragraph>
                        <paragraph>Inform male patients that yeast infection of penis (e.g., balanitis or balanoposthitis) may occur, especially in uncircumcised males and patients with prior history. Provide them with information on the signs and symptoms of balanitis and balanoposthitis (rash or redness of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a7-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that serious hypersensitivity reactions, such as urticaria, rash, anaphylaxis, and angioedema, have been reported with INVOKANA. Advise patients to report immediately any signs or symptoms suggesting allergic reaction, and to discontinue drug until they have consulted prescribing physicians
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a8-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Bone Fracture</content>
                        </paragraph>
                        <paragraph>Inform patients that bone fractures have been reported in adult patients taking INVOKANA. Provide them with information on factors that may contribute to fracture risk
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31a9-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise pregnant women, and females of reproductive potential of the potential risk to a fetus with treatment with INVOKANA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>. Instruct females of reproductive potential to report pregnancies to their physicians as soon as possible.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31aa-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women that breastfeeding is not recommended during treatment with INVOKANA
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31ab-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Laboratory Tests</content>
                        </paragraph>
                        <paragraph>Inform patients that due to its mechanism of action, patients taking INVOKANA will test positive for glucose in their urine
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a427270-31ac-bf22-e063-6294a90aaa69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dose</content>
                        </paragraph>
                        <paragraph>If a dose is missed, advise patients to take it as soon as it is remembered unless it is almost time for the next dose, in which case patients should skip the missed dose and take the medicine at the next regularly scheduled time. Advise patients not to take two doses of INVOKANA at the same time.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2a427270-31ad-bf22-e063-6294a90aaa69"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Active ingredient made in Belgium</paragraph>
                  <paragraph>Manufactured for: 
  <br/>  Janssen Pharmaceuticals, Inc. 
  <br/>  Titusville, NJ 08560, USA
 </paragraph>
                  <paragraph>Licensed from Mitsubishi Tanabe Pharma Corporation</paragraph>
                  <paragraph>For patent information: www.janssenpatents.com</paragraph>
                  <paragraph>Â© Johnson &amp; Johnson and its affiliates 2013 â 2024</paragraph>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="medguide">
               <id root="2a427270-31ae-bf22-e063-6294a90aaa69"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="2%" align="left" valign="top"/>
                     <col width="17%" align="left" valign="top"/>
                     <col width="9%" align="left" valign="top"/>
                     <col width="10%" align="left" valign="top"/>
                     <col width="10%" align="left" valign="top"/>
                     <col width="10%" align="left" valign="top"/>
                     <col width="15%" align="left" valign="top"/>
                     <col width="27%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="7">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 12/2024Â Â Â Â </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="8" align="center" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Medication Guide 
       <br/>  INVOKANA
      
       <sup>Â®</sup>(in-vo-KAHN-uh) 
       <br/>  (canagliflozin) 
       <br/>  tablets, for oral use
     
      </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph ID="important">
                                 <content styleCode="bold">What is the most important information I should know about INVOKANA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">INVOKANA can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Diabetic ketoacidosis (increased ketones in your blood or urine) in people with type 1 and other ketoacidosis.</content>INVOKANA can cause ketoacidosis that can be life-threatening and may lead to death. Ketoacidosis is a serious condition which needs to be treated in a hospital. People with type 1 diabetes have a high risk of getting ketoacidosis. People with type 2 diabetes or pancreas problems also have an increased risk of getting ketoacidosis. Ketoacidosis can also happen in people who: are sick, cannot eat or drink as usual, skip meals, are on a diet high in fat and low in carbohydrates (ketogenic diet), take less than the usual amount of insulin or miss insulin doses, drink too much alcohol, have a loss of too much fluid from the body (volume depletion), or who have surgery or a procedure that requires not having food for a long time (prolonged fasting). Ketoacidosis can happen even if your blood sugar is less than 250 mg/dL. Your healthcare provider may ask you to periodically check ketones in your urine or blood.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Stop taking INVOKANA and call your healthcare provider or get medical help right away if you get any of the following. If possible, check for ketones in your urine or blood, even if your blood sugar is less than 250 mg/dL:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="4">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>stomach-area (abdominal) pain</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>tiredness</item>
                                 <item>trouble breathing</item>
                                 <item>ketones in your urine or blood</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Amputations. INVOKANA may increase your risk of lower limb amputations. Amputations mainly involve removal of the toe or part of the foot, however, amputations involving the leg, below and above the knee, have also occurred. Some people had more than one amputation, some on both sides of the body.</content>
                                    <br/>  You may be at a higher risk of lower limb amputation if you:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>have a history of amputation</item>
                                       <item>have heart disease or are at risk for heart disease</item>
                                       <item>have had blocked or narrowed blood vessels, usually in your leg</item>
                                       <item>have damage to the nerves (neuropathy) in your leg</item>
                                       <item>have had diabetic foot ulcers or sores</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you have new pain or tenderness, any sores, ulcers, or infections in your leg or foot.</content>Your healthcare provider may decide to stop your INVOKANA for a while if you have any of these signs or symptoms.
    
     </paragraph>
                              <paragraph>Talk to your healthcare provider about proper foot care.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Dehydration. INVOKANA can cause some people to become dehydrated (the loss of too much body water). Dehydration may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). There have been reports of sudden worsening of kidney function in people with type 2 diabetes who are taking INVOKANA.</content>
                                    <br/>  You may be at higher risk of dehydration if you:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>take medicines to lower your blood pressure, including diuretics (water pill)</item>
                                       <item>are on a low sodium (salt) diet</item>
                                       <item>have kidney problems</item>
                                       <item>are 65 years of age or older</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>Talk to your healthcare provider about what you can do to prevent dehydration including how much fluid you should drink on a daily basis. Call your healthcare provider right away if you reduce the amount of food or liquid you drink, for example if you cannot eat or you start to lose liquids from your body, for example from vomiting, diarrhea, or being in the sun too long.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Vaginal yeast infection.</content>Women who take INVOKANA may get vaginal yeast infections. Yeast infections can be a serious but common side effect of INVOKANA. Symptoms of a vaginal yeast infection include:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>vaginal odor</item>
                                       <item>white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese)</item>
                                       <item>vaginal itching</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Yeast infection of the skin around the penis (balanitis or balanoposthitis).</content>Men who take INVOKANA may get a yeast infection of the skin around the penis. Men who are not circumcised may have swelling of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of yeast infection of the penis include:
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="5" align="left">
                              <list listType="unordered" styleCode="Circle">
                                 <item>redness, itching, or swelling of the penis</item>
                                 <item>foul smelling discharge from the penis</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>rash of the penis</item>
                                 <item>pain in the skin around penis</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>Talk to your healthcare provider about what to do if you get symptoms of a yeast infection of the vagina or penis. Your healthcare provider may suggest you use an over-the-counter antifungal medicine. Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is INVOKANA?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>INVOKANA is a prescription medicine used:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>along with diet and exercise to lower blood sugar (glucose) in adults and children aged 10 years and older with type 2 diabetes.</item>
                                       <item>to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes who have known cardiovascular disease.</item>
                                       <item>to reduce the risk of end stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine.</item>
                                    </list>
                                 </item>
                                 <item>INVOKANA is not recommended to decrease blood sugar (glucose) in people with type 1 diabetes.</item>
                                 <item>INVOKANA is not recommended to decrease blood sugar (glucose) in people with type 2 diabetes with severe kidney problems.</item>
                                 <item>It is not known if INVOKANA is safe and effective in children under 10 years of age.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph ID="shouldnot">
                                 <content styleCode="bold">Do not take INVOKANA if you</content>:
    
     </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to canagliflozin or any of the ingredients in INVOKANA. See the end of this Medication Guide for a list of ingredients in INVOKANA. Symptoms of allergic reaction to INVOKANA may include:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>rash</item>
                                       <item>raised red patches on your skin (hives)</item>
                                       <item>swelling of the face, lips, mouth, tongue, and throat that may cause difficulty in breathing or swallowing</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking INVOKANA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have type 1 diabetes or have had diabetic ketoacidosis.</item>
                                 <item>have a decrease in your insulin dose.</item>
                                 <item>have a serious infection.</item>
                                 <item>have a history of infection of the vagina or penis.</item>
                                 <item>have a history of amputation.</item>
                                 <item>have had blocked or narrowed blood vessels, usually in your leg.</item>
                                 <item>have damage to the nerves (neuropathy) in your leg.</item>
                                 <item>have had diabetic foot ulcers or sores.</item>
                                 <item>have kidney problems.</item>
                                 <item>have liver problems.</item>
                                 <item>have a history of urinary tract infections or problems with urination.</item>
                                 <item>are on a low sodium (salt) diet. Your healthcare provider may change your diet or your dose of INVOKANA.</item>
                                 <item>are going to have surgery or a procedure that requires not having food for a long time (prolonged fasting). Your healthcare provider may stop your INVOKANA before you have surgery. Talk to your healthcare provider if you are having surgery about when to stop taking INVOKANA and when to start it again.</item>
                                 <item>are eating less or there is a change in your diet.</item>
                                 <item>are dehydrated.</item>
                                 <item>have or have had problems with your pancreas, including pancreatitis or surgery on your pancreas.</item>
                                 <item>drink alcohol very often, or drink a lot of alcohol in the short-term ("binge" drinking).</item>
                                 <item>have ever had an allergic reaction to INVOKANA.</item>
                                 <item>are pregnant or plan to become pregnant. INVOKANA may harm your unborn baby. If you become pregnant while taking INVOKANA, tell your healthcare provider as soon as possible. Talk with your healthcare provider about the best way to control your blood sugar while you are pregnant.</item>
                                 <item>are breastfeeding or plan to breastfeed. INVOKANA may pass into your breast milk and may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking INVOKANA. Do not breastfeed while taking INVOKANA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    
     </paragraph>
                              <paragraph>INVOKANA may affect the way other medicines work, and other medicines may affect how INVOKANA works. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take INVOKANA?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take INVOKANA by mouth 1 time each day exactly as your healthcare provider tells you to take it.</item>
                                 <item>Your healthcare provider will tell you how much INVOKANA to take and when to take it. Your healthcare provider may change your dose if needed.</item>
                                 <item>It is best to take INVOKANA before the first meal of the day.</item>
                                 <item>Your healthcare provider may tell you to take INVOKANA along with other diabetes medicines. Low blood sugar can happen more often when INVOKANA is taken with certain other diabetes medicines. See "
      
       <content styleCode="bold">
                                       <linkHtml href="#sideeffects">What are the possible side effects of INVOKANA?</linkHtml>
                                    </content>"
     
      </item>
                                 <item>Your healthcare provider may tell you to stop taking INVOKANA at least 3 days before any surgery or procedure that requires not having food or water for a long time (prolonged fasting).</item>
                                 <item>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take two doses of INVOKANA at the same time. Talk to your healthcare provider if you have questions about a missed dose.</item>
                                 <item>If you take too much INVOKANA, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                                 <item>When your body is under some types of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine you need may change. Tell your healthcare provider right away if you have any of these conditions and follow your healthcare provider's instructions.</item>
                                 <item>INVOKANA will cause your urine to test positive for glucose.</item>
                                 <item>Your healthcare provider may do certain blood tests before you start INVOKANA and during treatment as needed. Your healthcare provider may change your dose of INVOKANA based on the results of your blood tests.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph ID="sideeffects">
                                 <content styleCode="bold">What are the possible side effects of INVOKANA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">INVOKANA may cause serious side effects including:</content>
                              </paragraph>
                              <paragraph>See "
     
      <content styleCode="bold">
                                    <linkHtml href="#important">What is the most important information I should know about INVOKANA?</linkHtml>
                                 </content>"
    
     </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">serious urinary tract infections.</content>Serious urinary tract infections that may lead to hospitalization have happened in people who are taking INVOKANA. Tell your healthcare provider if you have any signs or symptoms of a urinary tract infection such as a burning feeling when passing urine, a need to urinate often, the need to urinate right away, pain in the lower part of your stomach (pelvis), or blood in the urine. Sometimes people may also have a fever, back pain, nausea, or vomiting.
     
      </item>
                                 <item>
                                    <content styleCode="bold">low blood sugar (hypoglycemia).</content>If you take INVOKANA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKANA. 
       <br/>  Signs and symptoms of low blood sugar may include:
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Circle">
                                 <item>headache</item>
                                 <item>confusion</item>
                                 <item>hunger</item>
                                 <item>shaking or feeling jittery</item>
                              </list>
                           </td>
                           <td colspan="2" align="left">
                              <list listType="unordered" styleCode="Circle">
                                 <item>drowsiness</item>
                                 <item>dizziness</item>
                                 <item>fast heartbeat</item>
                              </list>
                           </td>
                           <td colspan="3" align="left" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>weakness</item>
                                 <item>irritability</item>
                                 <item>sweating</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">a rare but serious bacterial infection that causes damage to the tissue under the skin (necrotizing fasciitis) in the area between and around the anus and genitals (perineum).</content>Necrotizing fasciitis of the perineum has happened in people who take INVOKANA. Necrotizing fasciitis of the perineum may lead to hospitalization, may require multiple surgeries, and may lead to death.
      
       <content styleCode="bold">Seek medical attention immediately if you have fever or you are feeling very weak, tired or uncomfortable (malaise) and you develop any of the following symptoms in the area between and around your anus and genitals:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>pain or tenderness</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>swelling</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>redness of the skin (erythema)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">serious allergic reaction.</content>If you have any symptoms of a serious allergic reaction, stop taking INVOKANA and call your healthcare provider right away or go to the nearest hospital emergency room. See
      
       <content styleCode="bold">"
       
        <linkHtml href="#shouldnot">Do not take INVOKANA if you:</linkHtml>"
      
       </content>. Your healthcare provider may give you a medicine for your allergic reaction and prescribe a different medicine for your diabetes.
     
      </item>
                                 <item>
                                    <content styleCode="bold">broken bones (fractures).</content>Bone fractures have been seen in patients taking INVOKANA. Talk to your healthcare provider about factors that may increase your risk of bone fracture.
     
      </item>
                              </list>
                              <paragraph>The most common side effects of INVOKANA include:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>vaginal yeast infections and yeast infections of the penis (See "
      
       <content styleCode="bold">
                                       <linkHtml href="#important">What is the most important information I should know about INVOKANA?</linkHtml>
                                    </content>")
     
      </item>
                                 <item>changes in urination, including urgent need to urinate more often, in larger amounts, or at night</item>
                              </list>
                              <paragraph>These are not all the possible side effects of INVOKANA.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                              </paragraph>
                              <paragraph>You may also report side effects to Janssen Pharmaceuticals, Inc. at 1-800-526-7736.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store INVOKANA?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store INVOKANA at room temperature between 68 Â°F to 77 Â°F (20 Â°C to 25 Â°C).</item>
                                 <item>
                                    <content styleCode="bold">Keep INVOKANA and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of INVOKANA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use INVOKANA for a condition for which it was not prescribed. Do not give INVOKANA to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information about INVOKANA that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in INVOKANA?</content>
                              </paragraph>
                              <paragraph>Active ingredient: canagliflozin</paragraph>
                              <paragraph>Inactive ingredients: croscarmellose sodium (E468), hydroxypropyl cellulose (E463), lactose anhydrous, magnesium stearate (E572), and microcrystalline cellulose (E460[i]). In addition, the tablet coating contains iron oxide yellow (E172) (100 mg tablet only), macrogol/PEG3350 (E1521), polyvinyl alcohol (E1203) (partially hydrolyzed), talc (E553b), and titanium dioxide (E171).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="8" styleCode="Lrule Rrule">
                              <paragraph>Active ingredient made in Belgium. Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560, USA. 
      <br/>  Licensed from Mitsubishi Tanabe Pharma Corporation. For patent information: www.janssenpatents.com Â© Johnson &amp; Johnson and its affiliates 2013 â 2024 
      <br/>
                                 <content styleCode="bold">For more information about INVOKANA, call 1-800-526-7736 or visit our website at www.invokana.com.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="id_link_30ca5c53-64d5-3441-e063-6394a90ace80">
               <id root="30ca4dd9-2bfe-52d3-e063-6294a90a70df"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 50458-140-90</paragraph>
                  <paragraph>Invokana 
  <sup>Â®</sup>
                     <br/>
(canagliflozin) tablets
 </paragraph>
                  <paragraph>100 mg</paragraph>
                  <paragraph>Attention: Dispense the enclosed
  <br/>
Medication Guide to each patient.
 </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>90 tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_30ca4cc7-7079-54ef-e063-6394a90a040f"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="img_30ca4cc7-7079-54ef-e063-6394a90a040f">
                     <text>100mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Invokana_Tablet_100 mg_90 Tabs_Bottle label_10280906.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_30ca4cc7-70b4-54ef-e063-6394a90a040f">
               <id root="30ca6011-ad55-9039-e063-6294a90a6671"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 300 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 50458-141-90</paragraph>
                  <paragraph>Invokana 
  <sup>Â®</sup>
                     <br/>
(canagliflozin) tablets
 </paragraph>
                  <paragraph>300 mg</paragraph>
                  <paragraph>Attention: Dispense the enclosed
  <br/>
Medication Guide to each patient.
 </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>90 tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_30ca5f06-cb4d-837e-e063-6294a90af8cf"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="img_30ca5f06-cb4d-837e-e063-6294a90af8cf">
                     <text>300mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Invokana_Tablets_300 mg_90 Tabs_Bottle label_10281205.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>